Introduction {#sec1}
============

Toll-like Receptor 4 (TLR4) is a mammalian transmembrane receptor protein which, in complex with a myeloid differentiation factor 2 (MD-2), detects picomolar concentrations of Gram-negative bacterial endotoxin (or lipopolysaccharide, LPS) (Figure [1](#fig1){ref-type="fig"}A) and initiates an inflammatory signaling cascade aimed at the eradication of bacterial infection.^[@ref1]^ Activation of the innate immune response through TLR4·MD-2-LPS complex was shown to contribute to the pathogenesis of numerous inflammatory, autoimmune, and chronic diseases, such as sepsis syndrome, asthma, arthritis, and cancer, which highlights the significance of TLR4-MD-2 complex as a therapeutic target.^[@ref2]−[@ref5]^ Therapeutic modulation of the innate immune response by intervention with TLR4·MD-2 signaling has grown to a "hot" topic in the past decade.^[@ref4],[@ref6]^ Moreover, activation of TLR4 has been proposed to bridge the innate and adaptive immunity,^[@ref7]^ emphasizing stimulation of the TLR4·MD-2 complex by nontoxic ligands as a straightforward way to efficient vaccine adjuvants.^[@ref8]−[@ref10]^

Lipid A, an amphiphilic membrane-bound portion of LPS, represents the major pathogen-associated molecular pattern which drives the activation of TLR4 by binding to the co-receptor protein MD-2 and triggering the dimerization of two TLR4·MD-2·LPS complexes.^[@ref11]^ Generally, the binding of hexaacylated bisphosphorylated Lipid A (such as from *Escherichia coli*, Figure [1](#fig1){ref-type="fig"}B) by human TLR4·MD-2 complex results in the efficient activation of the innate immune response, whereas underacylated Lipid A variants are either inactive or antagonistic (such as tetraacylated lipid IVa, or the synthetic drug candidate Eritoran).^[@ref12],[@ref13]^ The co-crystal structures of the *E. coliRe*- and *Ra*-LPS with mouse (m) or human (h) MD-2·TLR4 complex, respectively, unravel that only five long-chain acyl residues of the hexaacylated Lipid A are incorporated into the hydrophobic binding pocket of MD-2 whereas the sixth 2-*N*-acyl chain is exposed on the surface of MD-2 and is involved in the dimerization interface with the second TLR4\*·MD-2\*-LPS complex (Figure [1](#fig1){ref-type="fig"}C).^[@ref14],[@ref15]^ The Phe126 residue of MD-2 is proposed to stabilize the presentation of an acyl tail on the surface of the protein and to serve as hydrophobic switch allowing dimerization to occur.^[@ref16],[@ref17]^ LPS-driven homodimerization of TLR4·MD-2-LPS complexes initiates recruitment of adaptor proteins to the intracellular TIR (Toll/interleukin-1 receptor) domains of TLR4 which ultimately results in the induction of the intracellular inflammatory signaling cascade.^[@ref18]^ In contrast, submerging of all lipid chains of the ligand into the hydrophobic binding groove of MD-2 results in an efficient binding without initiation of signaling, which is a characteristic feature of TLR4·MD-2 antagonists.^[@ref12],[@ref13]^

![(A) Structure of LPS, with *Re*-LPS and Lipid A. (B) Structures of TLR4 agonist *E. coli* Lipid A and MPLA. (C) Co-crystal structure of *E. coliRa*-LPS-hMD-2·TLR4 (PDB code: 3FXI; only Lipid A portion of LPS is shown for clarity), top and side views. Phe126 (orange) together with 2-*N*-acyl chain (yellow) creates a hydrophobic patch at the dimerization interface with the second TLR4\*·MD-2\* complex (brown). Positively charged Arg and Lys (blue) at the rim of the binding pocket of MD-2 are involved in the ionic interactions with the Lipid A phosphates. Images were generated with PyMol.](jm-2014-00946r_0002){#fig1}

The presence of both 1- and 4′-phosphate groups of Lipid A was shown to be crucial for the efficiency of the dimerization and the potency of the initiated signaling.^[@ref19]^ The absence of 1-phosphate leads to less efficient dimerization^[@ref20],[@ref21]^ and dampened cytokine production while maintaining sufficient TLR4-mediated immune activation and full adjuvant activity, which guided the development of monophosphoryl Lipid A (MPLA), a licensed vaccine adjuvant (Figure [1](#fig1){ref-type="fig"}B).^[@ref8],[@ref10]^

Despite tremendous intensive research on the interaction of TLR4·MD-2 complex with isolated,^[@ref22],[@ref23]^ genetically engineered,^[@ref24]^ and synthetic Lipid A's and analogues,^[@ref25]−[@ref29]^ the structure--activity relationships of the LPS-triggered TLR4 activation are not unambiguously established. Minor variations in the length and distribution pattern of fatty acyl chains in Lipid A typically result in dramatic amendment of TLR4-mediated immune signaling^[@ref25]−[@ref27]^ which cannot be rationally predicted.

We have addressed the challenges associated with the exploration of structural basis of LPS-induced TLR4 activation by development of a novel type of Lipid A mimetics wherein the flexible βGlcN(1→6)GlcN backbone of Lipid A is replaced by the conformationally restricted (1↔1)-connected disaccharide scaffolds. Notably, all Lipid A analogues synthesized so far were based either on the native β(1→6)-diglucosamine or on the more flexible backbones wherein one or both GlcN residues were replaced by a linear aglycon.^[@ref9],[@ref10],[@ref27],[@ref30]^ Previously we reported on the synthesis and potent anti-endotoxic activity of tetraacylated Lipid A mimetics derived from the β,α(1↔1)-linked diglucosamine representing an "antagonistically" shaped scaffold.^[@ref31]^

Taking advantage of a striking similarity between the conformation of the nonreducing sugar trehalose \[αGlc(1↔1)αGlc\] and the molecular shape of the β(1→6) diglucosamine backbone of TLR4·MD-2-bound agonist *E. coli* Lipid A disclosed in the X-ray structure, we have developed novel agonistic conformationally confined Lipid A mimetics based on the two-bond-linked rigid trehalose-type αGlcN(1↔1)αMan scaffold (Figure [2](#fig2){ref-type="fig"}).

![Structure of Lipid A mimetics (α,α-GM-LAMs) **1**--**3** based on the conformationally confined αGlcN(1↔1)αMan scaffold.](jm-2014-00946r_0003){#fig2}

Results and Discussion {#sec2}
======================

X-ray Structure-Guided Design of αGlcN(1↔1)αMan-Based Lipid A Mimetics {#sec2.1}
----------------------------------------------------------------------

The β(1→6) diglucosamine backbone represents the most conserved part of Lipid A, whereas its acylation and phosphorylation pattern varies within bacterial species.^[@ref22],[@ref32]^ The overall three-dimensional conformation of the intrinsically flexible three-bond-linked βGlcN(1→6)GlcN backbone of Lipid A is determined by the values of the dihedral angles ω, ϕ, and ψ about (1→6) glycosidic and oxymethyl linkages (Figure [3](#fig3){ref-type="fig"}A). Thus, the relative orientation of GlcN rings can be easily adapted by rotation about glycosidic and oxymethyl linkages via altering the corresponding torsion angles. This permits spontaneous adjustment of the shape of Lipid A to the geometry of the binding pocket of MD-2, which complicates the estimation of the "active" conformation of the ligand in the \[Lipid A-MD-2·TLR4\]~2~ complex. As seen in the co-crystal structures, the proximal (reducing) GlcN ring of MD-2-bound hexaacylated Lipid A adopts an inclined (or "twisted") orientation which, as we assume, is essential for the exposure of the long-chain 2-*N*-acyl residue on the surface of MD-2 followed by dimerization with the second MD-2·TLR4 complex (Figure [3](#fig3){ref-type="fig"}A,B).^[@ref31]^

![X-ray structure-based design of α,α-GM-LAMs. (A) Adjustment of the torsion angles about the (1→6) glycosidic linkage in the diglucosamine backbone of Lipid A upon binding by MD-2 results in a "twisted" orientation of the proximal GlcN ring for an agonist and in a coplanar orientation of the two GlcN rings for antagonist. (B) The proximal GlcN moiety of MD-2-bound *E. coli* Lipid A (PDB code 3FXI) adopts inclined orientation which allows the exposure of the 2-*N*-acyl chain.^[@ref31]^ Image was generated with PyMol. (C) The molecular shape of α,α-trehalose (crystal structure)^[@ref35],[@ref37]^ resembles the three-dimensional arrangement of βGlcN(1→6)GlcN backbone of the MD-2-bound *E. coli* Lipid A. (D) Structure of αGlcN(1↔1)αMan-based Lipid A mimetic (α,α-GM-LAM) **1** and proposed interaction of **1** with MD-2.](jm-2014-00946r_0004){#fig3}

To explore the structural prerequisites needed for an effective receptor complex homodimerization, we have manipulated the flexibility of the carbohydrate backbone of Lipid A by fixing its molecular shape in an "agonistic" conformation. Since the relative spatial arrangement of the two GlcN rings of MD-2-bound agonist *E. coli* Lipid A disclosed in the co-crystal structures^[@ref14],[@ref15]^ resembles the arrangement of α,α-(1↔1)-connected glucoses in the nonreducing disaccharide trehalose (Figure [3](#fig3){ref-type="fig"}B,C), we have developed predictably agonistic Lipid A mimetics based on the conformationally confined α,α-trehalose-like αGlcN(1↔1)αMan scaffold (Figure [3](#fig3){ref-type="fig"}D).

The values for the torsion angles Φα and Φ′α, representing rings orientation about the α,α-(1↔1) glycosidic linkage (Figure [3](#fig3){ref-type="fig"}D), are governed mostly by the anomeric and exo-anomeric effects and are only marginally dependent on the nature of functional groups in variably substituted α,α-trehaloses.^[@ref33]^ The existence of a single conformational minimum with respect to the dihedrals about glycosidic linkage in α,α-trehaloses was confirmed by molecular dynamics simulations,^[@ref33],[@ref34]^ whereas the preferred *gauche--gauche* conformation of the substituted α,α-trehalose^[@ref35]^ and its αGlc(1↔1)αMan analogue^[@ref36]^ was corroborated by X-ray and conformational analysis, respectively. Thus, conformationally restrained α,α-(1↔1) glycosidic linkage in αGlcN(1↔1)αMan-based Lipid A mimetics would impose a specific relative orientation of sugar rings resembling the molecular shape of the diglucosamine backbone of the agonistic MD-2-bound Lipid A.

αGlcN(1↔1)αMan-based Lipid A mimetics (α,α-GM-LAMs) **1**--**3** were designed such that the acylation and phosphorylation pattern of the nonreducing (distal) GlcN residue of *E. coli* Lipid A remains unaffected, whereas the β(1→6) glycosidic linkage is substituted by an α,α(1↔1) glycosidic bond and the reducing (proximal) GlcN moiety of natural Lipid A is exchanged for a nonreducing sugar (mannose) having a specific acylation and phosphorylation pattern (Figure [3](#fig3){ref-type="fig"}D). The location of the phosphate functionality at C-6 of the Man residue was selected to closely resemble the positioning of a 1-phosphate group of *E. coli* lipid A at the secondary dimerization interface of the TLR4-MD-2-Lipid A complex (PDB code 3FXI). The site of acylation at the mannose moiety was chosen such that the attachment of the long-chain (*R*)-3-acyloxyacyl residue at Man C-4 would provide a sufficient hydrophobic patch to support the homodimerization and the interaction with the second TLR4\*·MD-2\*-ligand complex.

Upon interaction with the receptor complex, the tetraacylated GlcN unit of α,α-GM-LAMs **1**--**3** was supposed to be fully accommodated within the hydrophobic pocket of MD-2, whereas the "twisted" mannose ring should be excluded from the binding site on MD-2 such that the two lipid chains at Man C-4 are presented onto the surface of the protein and involved in the secondary dimerization interface (Figure [3](#fig3){ref-type="fig"}D). The axial configuration at C-2 of mannose should provide, according to the crystal structures, a better fitting to the geometry of the binding pocket of MD-2 and, simultaneously, ensure easier stereocontrol in the 1,2-*trans* glycosylation step to α,α(1↔1)-linked disaccharide.

Synthetic Strategy {#sec2.2}
------------------

The assembly of αGlcN(1↔1)αMan, a 1,1-glycosidically connected (nonreducing) disaccharide, represents a formidable synthetic challenge with regard to simultaneous stereocontrol at two anomeric centers. Typically, approaches involving conventional glycosylation procedures for the synthesis of trehalose provide moderate stereoselectivity and low yields.^[@ref38]^ Since we aimed to establish the α,α-(1↔1) glycosidic linkage between an amino sugar and a *manno*-configured monosaccharide, we could hardly rely on the intramolecular aglycon delivery approach^[@ref39]^ or on the versatile synthetic desymmetrization of the natural trehalose.^[@ref40]^

![Synthetic Strategy toward Hexaacylated α,α-GM-LAMs **1**--**3**](jm-2014-00946r_0009){#sch1}

For the synthesis of bis- and monophosphorylated Lipid A mimetics **1**--**3** (Figure [2](#fig2){ref-type="fig"}) having non-symmetrically distributed acyloxyacyl functional groups, a convergent approach involving first the preparation of the orthogonally protected αGlcN(1↔1)αMan disaccharide scaffold followed by regioselective phosphorylation and acylation with (*R*)-3-acyloxyacyl fatty acids of variable chain lengths was envisaged (Scheme [1](#sch1){ref-type="scheme"}). For the assembly of the αGlcN(1↔1)αMan backbone, a 2-*N*-carbamate-protected glucosamine-based lactol was chosen as acceptor, and a 2-*O*-levulinoyl (Lev, 4-oxopentanoyl)-protected mannose was selected to serve as glycosyl donor. The participating protecting group at C-2 (Lev) should allow for a preferable 1,2-*trans* mannosylation. Since the 2-*O*-Lev protection had to be exchanged for a 2-*O*-Me group later in the synthesis, an alternative glycosylation approach using non-participating methyl protection at C-2 of the mannose-based donor was planned to be explored as well.

The 2-*N*-carbamates of variably protected GlcN-based lactols revealed the highest α/β ratio (up to 9:1) of the anomeric 1-OH group, which highlighted these intermediates as the most "stereoselective" glycosyl acceptors. Apparently, the presence of a carbamate N--H capable of hydrogen bonding with the axial oxygen at C-1 is responsible for the substantial enrichment with the α-anomer.

Synthesis of αGlcN(1↔1)αMan Scaffold {#sec2.3}
------------------------------------

To minimize the number of required orthogonal protecting groups, we intended the use of a GlcN acceptor with the pre-installed phosphate group at C-4, whereas C-6 was permanently and C-3 was temporarily protected. To this end, the 2-*N*-Troc-protected 4,6-di-*O*-benzylidene acetal **4**([@ref41]) was first acetylated to provide 3-*O*-acetate **5**, which was subjected to regioselective reductive opening of benzylidene acetal with Et~3~SiH/TfOH in CH~2~Cl~2~ to furnish 6-*O*-benzylated compound **6** (Scheme [2](#sch2){ref-type="scheme"}). Phosphitylation of 4-OH with bisbenzyl(diisopropylamino)phosphoramidite with 1*H*-tetrazole as catalyst followed by *in situ* oxidation with *meta*-chloroperbenzoic acid (*m*CPBA) afforded phosphotriester **7**. Compoud **7** was either desilylated at C-1 by treatment with pyridinium hydrofluoride (HF·Py) in THF to provide a 2-*N*-Troc-protected axially configured lactol **8** (α/β = 9:1) or processed to the 2-*N*-(9-fluorenylmethyl)carbamate (Fmoc)-protected counterpart **9**, which was similarly deprotected at C-1 to furnish anomeric lactol **10**, again with a high preponderance of the α-anomer (α/β = 9:1).

![Synthesis of Glucosamine Lactol Acceptors **8** and **10**\
Reagents and conditions: (a) Ac~2~O, DMAP, pyridine, 97%; (b) Et~3~SiH, TfOH, 4 Å MS, −78 °C, CH~2~Cl~2~, 68%; (c) 1. (BnO)~2~PN(*i*Pr)~2~, 1*H*-tetrazole, CH~2~Cl~2~, 2. *m*CPBA, −78 °C, 90%; (d) HF·Py, THF, 91% for **8**, 94% for **10**; (e) 1. Zn, AcOH, CH~2~Cl~2~, 2. FmocCl, EtN(*i*Pr)~2~, CH~2~Cl~2~, 89%.](jm-2014-00946r_0010){#sch2}

The synthesis of the required mannose-based donors commenced with Zemplén deacetylation of the peracetylated thioethyl glycoside **11**,^[@ref42]^ followed by introduction of a 4,6-di-*O*-*tert*-butylsilylene (DTBS) group in **12** (Scheme [3](#sch3){ref-type="scheme"}). Regioselective benzylation at C-3 via stannylene acetal intermediate and the agency of benzyl bromide in the presence of (*n*Bu)~4~NI furnished alcohol **13** in 93% yield. The 2-OH group was either levulinoyl-protected by reaction with 4-oxopentanoic acid, *N*,*N*′-diisopropylcarbodiimide (DIC), and a catalytic amount of 4-*N*,*N*-(dimethylamino)pyridine (DMAP) to give 2-*O*-levulinate ester **14** (90%) or methylated by reaction with MeI/NaH in DMF to provide 2-*O*-methyl ether **15** in 84% yield. Anomeric deprotection with *N*-bromosuccinimide (NBS) in aqueous acetone afforded lactols **16** and **17**, respectively, which were converted to trichloroacetimidates (TCA) **18** and **20** or to *N*-phenyl-trifluoroacetimidate (NPTFA) donors^[@ref43]^**19** and **21**.

![Synthesis of Mannose-Based Donors\
Reagents and conditions: (a) 1. NaOMe, MeOH, 2. (*t*Bu)~2~Si(OTf)~2~, pyridine, DMF, −35 °C, 89%; (b) 1. (*n*Bu)~2~SnO, toluene, 2. BnBr, (*n*Bu)~4~NI, DMF, toluene, reflux, 93%; (c) →**14**: LevOH, DIC, DMAP, CH~2~Cl~2~, 90%; (d) →**15**: MeI, NaH, DMF, 84%; (e) NBS, acetone--H~2~O, 24:1, 0 °C, 77% for **16** and 89% for **17**; (f) →**18** and **20**: CCl~3~CN, DBU, CH~2~Cl~2~, 0 °C, 90% for **18** and 94% for **20**; (g) →**19** and **21**: CF~3~(NPh)CCl, K~2~CO~3~, acetone, 99% for **19** and 93% for **21**.](jm-2014-00946r_0011){#sch3}

The key point in our initial approach was to obtain a good double α-stereoselectivity in the glycosylation reaction between reducing acceptor **8** (α/β = 9:1) and the 2-*O*-levulinoyl-protected imidate donors **18** or **19**. The participating levulinoyl group at C-2 of the *manno*-configured donors **18** and **19** should allow for a selective 1,2-*trans* glycosylation. A survey of the literature revealed that a complete α-*manno* selectivity upon application of 2-*O*-Lev-protected mannosyl donors could be obtained with a variety of acceptors.^[@ref44],[@ref45]^

In an initial glycosylation attempt comprising coupling the TCA donor **18** and acceptor **8** using trimethylsilyl trifluoromethanesulfonate (TMSOTf) as promoter, an orthoester **23** was obtained as the major product (23%) along with a minor proportion of the target α,α-disaccharide **22** (8%) and a concurrently formed donor self-coupling product **24** (Scheme [4](#sch4){ref-type="scheme"}A, [Supplementary SI-Table 1](#notes-1){ref-type="notes"}). With the less reactive NPTFA donor **19** or with the thioethyl donor **14** the formation of the orthoester was not observed; however, the desired product **22** was isolated only in trace amounts.

![Initial Attempts toward the Synthesis of αGlcN(1↔1)αMan Scaffold\
Reagents and conditions: (a) 1. HF·Py, THF, 2. Ac~2~O, DMAP, pyridine, 85%; (b) NBS, acetone--H~2~O, 24:1, 0 °C, 89%; (c) CCl~3~CN, DBU, CH~2~Cl~2~, 67%; (d) TMSOTf (0.05 equiv), 4 Å MS, CH~2~Cl~2~, 0 °C; (e) (CF~3~CO)~2~O, CF~3~COOH, Et~3~SiH, CH~2~Cl~2~, 0 °C, 91%; (f) 1. (BnO)~2~PN(*i*Pr)~2~, 1*H*-tetrazole, CH~2~Cl~2~, 2. *m*CPBA, −78 °C, 91%; (g) 1. Zn, AcOH, CH~2~Cl~2~, 0 °C, 2. FmocCl, EtN(*i*Pr)~2~, CH~2~Cl~2~, 88%; (h) 1. \[Ir(COD)(Ph~2~MeP)~2~\]PF~6~, H~2~, THF, 2. I~2~, aq. THF, 86%.](jm-2014-00946r_0012){#sch4}

We have hypothesized that the diminished reactivity of the torsionally disarmed 4,6-di-*O*-cyclic-protected mannose donor was responsible for the glycosylation failure.^[@ref46]^ Accordingly, the 4,6-di-*O*-DTBS group in **14** was cleaved and substituted for two acetates to provide **25**, wherein the C5--C6 bond was unlocked from the disarming *trans*--*gauche* conformation.^[@ref46],[@ref47]^ To provide consistency with the previously performed imidate-mediated glycosylations, the thioglycoside at C-1 was exchanged for a TCA group to furnish **27** (Scheme [4](#sch4){ref-type="scheme"}B). The coupling of **8** and the torsionally unlocked 4,6-di-*O*-acetyl donor **27** resulted in the isolation of the α,α-configured disaccharide **28**, albeit in a similarly low yield (8%).

Thereafter, our attention was turned to the apparently low reactivity of the lactol acceptor **8** affected by the H-bonding between the α-1-OH and the carbamate NH groups. To increase the nucleophilicity of the lactol acceptor and to reduce steric constraints, the disarming acetate at C-3 was exchanged for a TBDMS group, and the sterically demanding 2-*N*-Troc group was replaced by Fmoc protection, which provided α-lactol acceptor **33**. To this end, compound **30**, made by a highly selective reductive opening of benzylidene acetal in the allyl glycoside **29**,^[@ref31]^ was phosphorylated at C-4 to give **31** (Scheme [4](#sch4){ref-type="scheme"}C). Reductive cleavage of 2-*N*-Troc protection with Zn in acetic acid followed by reaction with Fmoc chloride in the presence of a EtN(*i*Pr)~2~ furnished **32**, which was anomerically deprotected using \[Ir(COD)(Ph~2~MeP)~2~\]PF~6~-catalyzed isomerization of the allyl group followed by oxidative cleavage of the 1-propenyl group with I~2~ in THF--H~2~O to afford the "armed" acceptor **33**. Reaction of the 2-*O*-levulinoyl TCA donor **18** with **33**, however, reproducibly resulted in the formation of the orthoester **34** as the major product (Scheme [4](#sch4){ref-type="scheme"}C).

In retrospect, we assume that the failure of the 2-*O*-levulinoyl-protected mannose-based donors to provide the desired αGlcN(1↔1)αMan compound in a glycosylation reaction with GlcN-based lactol acceptors was rather related to a particular conformation of the arising trehalose-type α,α-disaccharide. A successful glycosylation would lead to a sterically hindered coupling product **22**, having overlapping bulky 2-*N*-Troc/Fmoc groups at the GlcN moiety and a linear 4-oxopentanoate (levulinate) ester group at C-2 of mannose, while reciprocal repulsion of the *N*-carbamate and electron-rich levulinoyl groups could contribute as well.

Given the failure of 2-*O*-levulinoyl-protected mannosyl donors to provide the desired coupling products, the participating protecting group at C-2 of mannose was exchanged for the 2-*O*-Me group as in the donors **20** and **21** (Scheme [3](#sch3){ref-type="scheme"}). Successful application of non-participating groups in the α-selective mannosylation has been extensively reported.^[@ref48],[@ref49]^ Gratifyingly, the coupling of the 2-*O*-Me-Man imidate donor **21** with the GlcN-lactol acceptor **8** allowed for a much higher isolated yield (51%) of the α,α-disaccharide **35** (Scheme [5](#sch5){ref-type="scheme"}, Table [1](#tbl1){ref-type="other"}, entry 2). Owing to the low reactivity of acceptor **8**, the NPTFA donor **21** was found to be superior to the TCA donor **20** due to the propensity of the latter to form substantial amounts of the rearranged glycosylamide **45** (52%), which is characteristic for glycosylations involving acceptors of diminished reactivity (Table [1](#tbl1){ref-type="other"}, entries 1 and 2). The isolation of the α,α-disaccharide **35** was complicated by the concomitant formation of the co-migrating αGlcN−βMan **38** and βGlcN−αMan **41** byproducts. Glycosylation of the 2-*N*-Fmoc-protected acceptor **10** by the NPTFA donor **21** afforded a similar isolated yield (52%) of the target α,α-configured disaccharide **36** (Scheme [5](#sch5){ref-type="scheme"}, Table [1](#tbl1){ref-type="other"}, entry 3).

![Synthesis of GlcN(1↔1)Man Disaccharides](jm-2014-00946r_0013){#sch5}

###### Outcome of (1↔1) Glycosylation Utilizing 2-*O*-Me-Protected Imidate Donors **20** and **21** (Scheme [5](#sch5){ref-type="scheme"})

![](jm-2014-00946r_0015){#fx1}

Enhancement of the acceptor reactivity by the use of 3-*O*-TBDMS-protected "armed" lactol **33** did not improve the yields in the coupling reactions with either donor **20** or **21** (Table [1](#tbl1){ref-type="other"}, entries 4 and 5), furnishing αGlcN(1↔1)αMan disaccharide **37** in 25% and 50% yield, respectively. The yield of the αGlcN(1↔1)αMan disaccharide was related to the ease of its chromatographic purification, which, in turn, was strongly dependent on the protection group pattern. Since isolation of the 2-*N*-Fmoc-3-*O*-Ac-protected **36** from the mixture of anomeric products was the most straightforward, this disaccharide was chosen for further transformation to the target α,α-GM-LAMs **1**--**3**.

The configurations at the anomeric centers of the (1↔1)-linked disaccharides were assigned on the basis of ^1^H and ^13^C NMR shifts at the anomeric positions and the ^1^*J*~C1,H1~ coupling constants^[@ref50]^ ([SI-Table 2](#notes-1){ref-type="notes"}). To circumvent the severe peak broadening in the ^1^H NMR spectrum, the Fmoc group in **42** was replaced by a 2-*N*-acetate to give acetamide **44** appropriate for the unambiguous signal assignment. The α,α-linkage in **35**--**37** was confirmed by the large ^1^*J*~C1,H1~ coupling constant values of the anomeric carbons (^1^*J*~C1,H1~ = 170--174 Hz for α-*manno*- and ^1^*J*~C1,H1~ = 173--178 Hz for α-*gluco*-anomers) and by the downfield shifts and the corresponding vicinal proton coupling constants ^3^*J*~H1,H2~ of the anomeric H-1 signals (δ 5.02--5.12, ^3^*J*~1,2~ = 1.5 Hz for α-*manno*- and 5.08--5.23, ^3^*J*~1,2~ ≈ 3.7 Hz for α-*gluco*-anomers).^[@ref51]^ The β-*manno* linkage in **38**--**40** was corroborated by the typically smaller ^1^*J*~C,H~ coupling constants for the anomeric carbons (^1^*J*~C1,H1~ = 155--157 Hz) and by the upfield shifts of the anomeric H-1 signals (4.6 ppm) and H-5 signals (3.28 ppm), characteristic for β-mannosides.^[@ref52]^

Synthesis of Lipid A Mimetics **1**--**3** Based on αGlcN(1↔1)αMan Scaffold {#sec2.4}
---------------------------------------------------------------------------

Having orthogonally protected αGlcN(1↔1)αMan disaccharide scaffold **36** in hand, we next approached the stepwise deprotection and acylation at C-2 and C-3 of the GlcN fragment. The feasibility of regioselective deacetylation at C-3 in the presence of the adjacent 2-*N*-Fmoc carbamate and the base-labile phosphotriester group at C-4 in **36** was first examined ([SI-Scheme 1](#notes-1){ref-type="notes"}). Among a variety of tested conditions, application of aqueous hydroxylamine provided the best reproducible results for the exclusive removal of 3-*O*-acetate ([SI-Table 3](#notes-1){ref-type="notes"}). Cleavage of the 3-*O*-Ac group to furnish **46** was accompanied by the migration of the phosphate from C-4 to the liberated hydroxyl group at C-3 to give **47** (Scheme [6](#sch6){ref-type="scheme"}). Besides, a partial hydrolytic loss of one benzyl protecting group in the phosphotriester **46** leading to formation of the phosphodiester **48** was also observed. Further improvements could be achieved through optimization of reaction conditions. Indeed, when the reaction was terminated prior to completion (48 h), the formation of the undesired byproducts **47** and **48** could be largely avoided (2% and 9%, respectively), providing 3-*O*-deacylated compound **46** in 53% yield ([SI-Table 3](#notes-1){ref-type="notes"}). Repeated chromatographic purifications of the disaccharide **46** partly account for the relatively low yield.

![Synthesis of αGlcN(1↔1)αMan-Based Lipid A Mimetics (α,α-GM-LAMs) **1**--**3**\
Reagents and conditions: (a) aq. 50% NH~2~OH, THF, 0 °C: **46** (53%), **47** (2%), **48** (9%), recovered **36** (15%); (b) **49**, DIC, DMAP, CH~2~Cl~2~, 0 °C, 83%; (c) DBU, CH~2~Cl~2~; (d) **50**, EDC, CHCl~3~; (e) HF·Py, THF; (f) →**57 + 59**, DIC, DMAP, **50**, CH~2~Cl~2~, 0 °C; (g) →**58** + **60**, DIC, DMAP, **51**, CH~2~Cl~2~, 0°C; (h) 1. (BnO)~2~PN(*i*Pr)~2~, 1*H*-tetrazole, CH~2~Cl~2~, 2) *m*CPBA, −78 °C, 91% for **61,** 89% for **62**; (i) Pd black, toluene--MeOH, 1:1, 72% for **1**, 87% for **2**, 81% for **3**.](jm-2014-00946r_0014){#sch6}

The first (*R*)-3-(tetradecanoyloxy)tetradecanoyl residue at C-3 of the GlcN moiety was introduced by reaction of **46** with β-acyloxyacyl acid **49** under the agency of DIC and a catalytic amount of DMAP to provide **52** in 83% yield (Scheme [6](#sch6){ref-type="scheme"}). Notably, strictly equimolar amounts of DIC and fatty acid **49**, and a catalytic quantity of DMAP at 0 °C, had to be applied to suppress the concomitant formation of the co-migrating 3-*O*-tetradecanoyl (**53**) and 3-*O*-alkenoyl (**54**) byproducts (11% and 3%, respectively). Application of higher amounts of DIC and/or fatty acid aimed to accelerate the transformation resulted in augmented formation of **53** and **54**, which could be rationalized by a probable β-elimination or rearrangement^[@ref53]^ of the *in situ*-formed *O*-acyl-oxyacylisourea intermediate. Formation of a 3-*O*-alkanoyl side product similar to **53** in the DIC/DMAP-mediated condensation had been previously reported, though no elimination byproduct such as **54** was detected.^[@ref30]^ Since esterification with β-acyloxyacyl fatty acids under Steglich conditions is routinely applied in the synthesis of Lipid A's and analogues which often display high bioactivity at picomolar doses, this finding is of importance for the preparation of Lipid A-based compounds of the uppermost purity.

Subsequent Fmoc cleavage in **52** with DBU followed by EDC-mediated *N*-acylation with (*R*)-3-(dodecanoyloxy)tetradecanoic acid **50** provided tetraacylated disaccharide **55**. Conversion of 4,6-di-*O*-DTBS derivative **55** into diol **56** was performed under standard conditions with HF·Py in THF. To introduce acyl and phosphate functional groups at mannose C-4 and C-6, respectively, without additional protecting group manipulation, the regioselectivity of the acylation of the diol **56** with the acyloxyacyl acids **50** or **51** was first examined. Since hydroxyl groups in the substituted trehaloses are known to differ in reactivity due to both steric and electronic effects,^[@ref38],[@ref40]^ we expected that, in a heavily substituted αGlcN(1↔1)αMan disaccharide **56**, positions C-4 and C-6 at the Man moiety could be discriminated in a subsequent acylation procedure.

Indeed, the major outcome of DIC/DMAP-mediated acylation of **56** with the acids **50** or **51** was not the intrinsically expected primary 6-OH-derived acylation products, but the 4-*O*-acyloxyacyl derivatives **57** and **58** in 51% and 65% yield, respectively, having a 6-OH group at the mannose unit accessible for the ensuing phosphorylation. Minor amounts of the 4,6-bis-*O*-acylated derivatives **59** and **60** (24% and 13%, respectively) were isolated as well. Although the 6-OH group of the mannose residue in αGlcN(1↔1)αMan disaccharide **56** is somewhat remote from the 2-NH of the GlcN moiety, the crystal structures of α,α-trehalose-based compounds indicate spatial proximity of the two groups. Thus, it could be assumed that the intramolecular hydrogen bonding (2-NH^GlcN^--6-OH^Man^) exerts an adverse effect on the reactivity of the primary hydroxyl group at Man C-6. Furthermore, the bulkiness of the *in situ*-formed acyloxyacyl-activated ester resulting from the reaction of the fatty acids **50** or **51** with DIC/DMAP could also explain the limited access to the sterically hindered 6-OH group in the α,α-trehalose-like disaccharide **56**.

Next, the free 6-OH group in the hexaacylated disaccharides **57** and **58** was phosphorylated by reaction with dibenzyl-(*N*,*N*′-diisopropylamino)phosphoramidite in the presence of a mild acid catalyst, 1*H*-tetrazole, and subsequent oxidation with *m*CPBA at −78 °C to furnish the bisphosphorylated hexaacylated products **61** and **62** in 91% and 89% yield, respectively. Final debenzylation by hydrogenation of **57**, **61**, and **62** on Pd-black followed by purification with gel permeation chromatography on Sephadex SX1 in toluene--methanol (2:1) afforded target bisphosphorylated Lipid A mimetics **1** and **2** and a monophosphorylated counterpart **3**. In contrast to native Lipid A, compounds **1** and **2** do not possess a labile anomeric phosphate functionality; consequently, they were isolated and biologically assessed as free acids at the phosphates and could be stored in aqueous solution at 4 °C for several months without any noticeable sign of degradation, which was confirmed by MALDI-TOF analysis.

Activation of TLR4·MD-2 Complex by α,α-GM-LAMs **1**--**3** {#sec2.5}
-----------------------------------------------------------

The propensity of the α,α-GM-LAMs **1**--**3** to stimulate TLR4-mediated immune signaling was first assessed in the hTLR4/hMD-2/CD14 transfected human embryonic kidney (HEK) 293 cells (HEK-Blue). Since we were particularly interested in the molecular recognition mechanisms implicated in the binding of LPS by the MD-2·TLR4 complex wherein the Lipid A/*Re*-LPS portion of LPS is exclusively involved, we evaluated the activities of α,α-GM-LAMs **1**--**3** compared to *E. coliRe*-LPS (Figure [1](#fig1){ref-type="fig"}A). It has been previously shown that the minimum structural requirement for the expression of the highest cytokine-inducing potency resides in *Re*-LPS, which entails two 3-deoxy-[d]{.smallcaps}-*manno*-oct-2-ulosonic acid (Kdo) residues in addition to Lipid A ([Supporting Information, SI-Figure 1A](#notes-1){ref-type="notes"}).^[@ref54],[@ref55]^ Moreover, the *Re*-LPS has a defined molecular weight (MW) similar to the MW range for Lipid A mimetics (1.8--2.2 kDa), in contrast to wild-type LPS having variable MW (10--15 kDa), so that the direct comparison of a dose-dependent response between compounds **1**--**3** and *Re*-LPS is more appropriate. The TLR4-stimulating activity of Lipid A mimetics **1**--**3** was examined over a wide concentration range by monitoring of the activation of the NF-κB regulated signal transduction pathway via measuring the induction of secreted embryonic alkaline phosphatase (SEAP) and compared to the responses elicited by *E. coliRe*-LPS and SM-MPLA.

Remarkably, the glycosylation at C-6′ of Lipid A with Kdo residues was reported to be responsible for the 10--20-fold enhancement of the activity of the Kdo/Kdo2-Lipid A (*Re*-LPS) compared to Lipid A alone in the nanomolar concentration range.^[@ref28],[@ref54]^ Notably, conformationally confined α,α-GM-LAM **2** based on just a disaccharide scaffold displayed NF-κB activation (EC~50~ = 0.08 nM) similar to those of *Re*-LPS (EC~50~ = 0.04 nM) and *E. coli* LPS (EC~50~ = 0.08 nM, [SI-Figure 1A](#notes-1){ref-type="notes"}), and the TLR4 saturation plateau was reached at a concentration of 1 ng/mL for both ligands (Figure [4](#fig4){ref-type="fig"}). Compound **1**, having a 2×CH~2~-longer acyl side chain at Man C-4 compared with α,α-GM-LAM **2**, was a less efficient activator of NF-κB (EC~50~ = 0.4 nM), so that its TLR4 saturation plateau was reached at a concentration of 5 ng/mL. Thus, shortening of a lipid side chain at C-4 of the mannose moiety by 2×CH~2~ resulted in a 5-fold increase of TLR-4 stimulating activity, which underlines the significance of hydrophobic interactions at the dimerization interface. Along this line, synthetic manipulation of the length of the acyl side chain at Man C-4 could be used for fine-tuning of the hTLR4-mediated activity in α,α-GM-LAMs. The monophosphate **3** was, as expected, significantly less active (EC~50~ = 31 nM) than its bisphosphorylated counterpart **1**, but it showed a more potent activation profile than SM-MPLA at concentrations above 10 ng/mL.

![Dose-dependent activation of TLR4 signaling in hTLR4/hMD-2/hCD14-transfected HEK293 cells (HEK-Blue) by Lipid A mimetics **1**--**3** compared to *E. coliRe*-LPS and *S. minnesota* MPLA.](jm-2014-00946r_0005){#fig4}

Modulation of the Expression of Cytokines by α,α-GM-LAMs **1**--**3** in Human and Mouse Macrophages {#sec2.6}
----------------------------------------------------------------------------------------------------

Lipid A mimetics **1**--**3** were examined for the ability to initiate the expression of tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), and monocyte chemotactic protein-1 (MCP-1) in the human monocytic macrophage-like cell line THP-1, which expresses MD-2, CD14, and a variety of cell surface receptors, including TLR4.

The dose-dependent stimulating activity of synthetic Lipid A mimetics was cytokine-specific, revealing higher potency in the induction of the expression of TNF-α and IL-8 by α,α-GM-LAMs **1** and **2** than by *Re*-LPS/LPS (Figure [5](#fig5){ref-type="fig"}A,B, [SI-Figures 2 and 3](#notes-1){ref-type="notes"}). The release of MCP-1 induced by α,α-GM-LAM **2** was clearly more effective than the production of this chemokine by *Re*-LPS and compound **1** (Figure [5](#fig5){ref-type="fig"}C). Expression of MyD88-dependent chemokine MCP-1 is associated with the activation of the intracellular TLR4·MD-2 complex.^[@ref56]^ The dampened induction of the expression of cytokines by α,α-GM-LAM **3** correlates to its chemical structure missing a phosphate group at Man C-6. Our results indicate that both α,α-GM-LAMs **1** and **2** are more potent activators of the MyD88 signaling pathway than *Re*-LPS/LPS (Figure [5](#fig5){ref-type="fig"}, [SI-Figure 4](#notes-1){ref-type="notes"}).

![Dose-dependent expression of cytokines induced by α,α-GM-LAMs **1**--**3** in human macrophage cell line THP-1 compared to *E. coliRe*-LPS. (A) Production of TNF-α. (B) Induction of the expression of IL-8. (C) Induction of release of MCP-1.](jm-2014-00946r_0006){#fig5}

The ability of Lipid A mimetics **1**--**3** to induce the production of TNF-α and IL-6 from bone marrow-derived macrophages (BMDM) in mice was subsequently examined and compared to that of synthetic *E. coli* Lipid A and *E. coli* MPLA, which are reliable positive controls due to their chemical purity and homogeneity (Figure [6](#fig6){ref-type="fig"}). The maximum level of TNF-α (4000 pg/mL) was detected in BMDM cultivated in the presence of 1 nM α,α-GM-LAM **1** or **2**, whereas the same quantity of the "parent" Lipid A resulted in release of half the amount of TNF-α (2000 pg/mL). On the other hand, monophosphoryl α,α-GM-LAM **3** exhibited a dampened ability to express TNF-α (500 pg/mL) at a concentration of 1 nM. Likewise, 1 nM (1.8 ng/mL) of **1** or **2** triggered the release of a 3-fold higher amount of IL-6 (1500 pg/mL) compared to Lipid A (500 pg/mL). Monophosphate **3** revealed a dose-dependent cytokine induction profile showing only marginal expression level of IL-6 at a concentration of 1 nM but higher IL-6 release than MPLA at concentrations above 1 nM.

![Induction of expression of TNF-α and IL-6 by Lipid A mimetics **1**--**3** in mBMDM compared to synthetic *E. coli* Lipid A and *E. coli* MPLA. *E. coli* O111:B4 LPS was used as positive control (1 nM).](jm-2014-00946r_0007){#fig6}

TLR4 Stimulating Activities of α,α-GM-LAMs **1** and **3** in Human Dendritic Cells {#sec2.7}
-----------------------------------------------------------------------------------

To test the impact of selected α,α-GM-LAMs **1** and **3** on maturation of human dendritic cells (hDCs), immature monocyte-derived hDCs were stimulated with **1** and **3** in a wide concentration range or with *E. coli* LPS as positive control. DCs are able to persistently sense pathogen-associated molecular patterns and present antigens to T lymphocytes, thereby initiating an adaptive immune response.^[@ref7]^ DCs treated with LPS acquired a distinctive morphologic phenotype and, when analyzed by flow cytometry, displayed characteristic markers of mature DCs.

Stimulation of DCs with **1** (1 mg/mL) was as potent as that with LPS in inducing DCs maturation and up-regulation of the co-stimulatory molecules CD86, as well as the antigen-presenting structures MHC class I and MHC class II, which are necessary for the induction of an adaptive immune response ([SI-Figure 5](#notes-1){ref-type="notes"}). None of the α,α-GM-LAMs exerted cytotoxic effects on DCs, as determined by propidium iodide staining (data not shown).

Activated DCs were examined for the production of pro-inflammatory cytokines TNF-α, IL-6, and IL-12, which contribute to the modulation of the T cell response and innate effector functions.^[@ref57]^ The release of TNF-α and IL-6 reached nearly maximum levels (attained with 10 ng/mL LPS) at the α,α-GM-LAM **1** concentration of 1 ng/mL (Figure [7](#fig7){ref-type="fig"}A). Also the expression of IL-12, which promotes the development of adaptive immune cells and is involved in coordinating innate and adaptive immunity,^[@ref58]^ was efficiently induced by α,α-GM-LAM **1**, indicating its potential adjuvant capacity. The release of TNF-α, IL-6, and IL-10, a unique cytokine with a wide spectrum of anti-inflammatory effects, in DCs induced by monophosphate **3** was, in agreement with the experiments in the recombinant hTLR4/hMD-2 signaling system, less efficient compared to that induced by **1** (Figure [7](#fig7){ref-type="fig"}B).

![Expression of cytokines induced by α,α-GM-LAMs **1** and **3** in human dendritic cells. (A) Induction of cytokine production by **1** in DCs. (B) Expression of TNF-α, IL-6, and IL-10 induced by monophoshorylated α,α-GM-LAM **3** compared to its bisphosphorylated counterpart **1**. *E. coli* LPS (10 ng/mL) was used as a positive control.](jm-2014-00946r_0008){#fig7}

Conclusions and Perspectives {#sec2.8}
============================

We have rationally designed, synthesized, and biologically evaluated an entirely novel type of TLR4 agonists based on the conformationally restrained disaccharide scaffold which mimics the spatial arrangement of (1→6) diglucosamine backbone of MD-2-bound *E. coli* Lipid A, revealed in the co-crystal structures of the TLR4·MD-2-LPS complexes. A convergent synthetic approach toward the αGlcN(1↔1)αMan scaffold and hexaacylated Lipid A mimetics based thereon has been developed. Orthogonally protected nonreducing αGlcN(1↔1)αMan disaccharide was assembled via imidate-mediated glycosylation by taking advantage of the axial orientation of the anomeric OH group in the 2-*N*-carbamate-protected GlcN-lactol acceptors. The protecting group pattern was fine-tuned to ensure stereospecific α,α-(1↔1) glycosylation and to afford efficient isolation of the α,α-disaccharide from the anomeric mixtures. Replacement of the labile anomeric 1-phosphate functionality (as in natural Lipid A) for a primary phosphate group in α,α-GM-LAMs **1** and **2** provides unambiguous advantages with respect to hydrolytic stability.

In spite of the lack of Kdo moieties which were demonstrated to be responsible for a 10--20-fold enhancement of the activity of *Re*-LPS (Kdo-Kdo-Lipid A) compared to Lipid A alone, the NF-κB activation efficacy and cytokine inducing capacity of bisphosphorylated Lipid A mimetics **1** and **2** in DCs and human macrophages were comparable to or higher than those of *Re*-LPS/LPS. The inherent rigidity of the α,α-(1↔1) glycosidic linkage in **1**--**3** would not allow for extensive conformational adjustment of the αGlcN(1↔1)αMan backbone to the shape of the binding pocket of MD-2, such that the three-dimensional arrangement of an α,α-GM-LAM molecule should remain preserved also in the protein-bound state. Accordingly, our results indicate that restricting the flexibility of the carbohydrate backbone of Lipid A in an "agonistic" conformation, as in α,α-GM-LAMs, allows the prearrangement of the phosphate and acyl groups in the "flipped" Man moiety in a defined conformation, which results in a very potent TLR4 activation ([SI-Figure 6](#notes-1){ref-type="notes"}). The shortening of a secondary acyl chain at Man C-4 and the presence of a phosphate group at Man C-6 significantly enhanced the TLR-4 stimulating activity, which indicates the involvement of these functionalities at the dimerization interface with the second TLR4\*·MD-2\*-ligand complex and opens opportunities for fine-tuning the activities of α,α-GM-LAMs by chemical modifications.

Since the molecular shape of αGlcN(1↔1)αMan-based Lipid A mimetics is believed to resemble the conformation of the MD-2-bound *E. coli* Lipid A in the active \[TLR4·MD-2-LPS\]~2~ complex, further immuno-biological studies of the interaction of α,α-GM-LAMs with TLR4·MD-2 would provide deeper insight into the molecular basis of TLR4 activation by LPS.

Along these lines, application of a conformationally restricted "agonistically" shaped disaccharide scaffold in place of the native βGlcN(1→6)GlcN Lipid A backbone appears to provide a useful tool for modulation of TLR4·MD-2-mediated immune signaling. Thus, synthetic αGlcN(1↔1)αMan-based Lipid A mimetics represent the key structures for the advanced development of pharmaceutically applicable immuno-therapeutics or vaccine adjuvant candidates.

Experimental Section {#sec3}
====================

General Synthetic Methods {#sec3.1}
-------------------------

Reagents and solvents were purchased from commercial suppliers and used without further purification unless otherwise stated. Dichloromethane was distilled from CaH~2~ and stored over activated 4 Å molecular sieves (MS). THF was distilled over Na/benzophenone directly prior to use. Other solvents were dried by storage over activated MS for at least 48 h prior to use \[toluene (4 Å), acetonitrile (3 Å), and DMF (3 Å)\]. Residual moisture was determined by colorimetric titration on a Mitsubishi CA-21 Karl Fischer apparatus and did not exceed 20 ppm for dry solvents. Reactions were monitored by TLC performed on silica gel 60 F254 HPTLC precoated glass plates with a 25 mm concentration zone (Merck). Spots were visualized by UV light followed by dipping into a H~2~SO~4~--*p*-anisaldehyde solution or a ninhydrin--EtOH solution and subsequent charring at 250 °C. Solvents were removed under reduced pressure at ≤30 °C. Preparative HPLC was performed with linear solvent gradients on a YMC Pack SIL-06 250 × 20 mm, S-5 μm, 6 nm column (Column A, loadings 50--150 mg), or on a YMC Pack SIL-06 250 × 10 mm, S-5 μm, 6 nm column (Column B, loadings 5--50 mg). Preparative MPLC was performed on silica gel 60 (230--400 mesh, Merck). Size exclusion chromatography was performed on Sephadex LH20 or Bio-Beads SX1 (BioRad) supports. NMR spectra were recorded at 298 K on a Bruker Avance III 600 spectrometer (^1^H at 600.22 MHz; ^13^C at 150.92 MHz; ^31^P at 242.97 MHz) or on a Bruker DPX 400 spectrometer (^1^H at 400.13 MHz; ^13^C at 100.61 MHz; ^31^P at 161.68 MHz) using standard Bruker NMR software. Chemical shifts are reported in ppm, where ^1^H NMR spectra in CDCl~3~ are referenced to internal TMS and ^13^C-spectra are referenced to the corresponding solvent signal (77.0 ppm for CDCl~3~). NMR spectra in other solvents are referenced to residual solvent signals (for acetone-*d*~6~, 2.05 and 29.84 ppm; for MeOD, 3.31 and 49.00 ppm, ^1^H and ^13^C NMR, respectively). ^31^P NMR spectra in CDCl~3~ are referenced according to IUPAC recommendations from 2001 from a referenced ^1^H NMR spectrum. In the disaccharides, the mannose NMR signals are indicated by primes. The purity (\>95%) was determined by LC-MS and HRMS. HPLC-MS was performed by injections of 0.01--0.1% CH~3~CN solutions into a Shimadzu LC-10AD VP system equipped with two gradient pumps, a degasser, a Shimadzu LCMS 2020 detector, and an AllTech 3300 ELSD detector. Analytes were eluted over a Phenomenex Jupiter 5μ C4 300A column using mobile phase A = H~2~O (0.1% HCOOH) and mobile phase B = CH~3~CN (0.1% HCOOH) in linear gradients from 5% B to 100% B and a flow rate of 0.5 mL/min. High-resolution mass spectrometry (HRMS) was carried out on 1--10 mg/L acetonitrile solutions via LC-TOF MS (Agilent 1200SL HPLC and Agilent 6210 ESI-TOF, Agilent Technologies). The mass spectrometer was tuned with Agilent tune mix to provide a mass accuracy below 2 ppm. The data were analyzed using Agilent Mass Hunter Software. MALDI-TOF MS was performed in the negative-ion mode using a Bruker Autoflex Speed instrument with 6-aza-2-thiothymine (ATT) as matrix. Optical rotation was measured on a PerkinElmer 243B polarimeter equipped with a Haake water circulation bath and a Haake D1 immersion circulator for temperature control. All \[α\]~D~^20^ values are reported in units of deg·dm^--1^·cm^3^·g^--1^.

### 3-*O*-Benzyl-4,6-*O*-di-*tert*-butylsilylene-2-*O*-methyl-α-[d]{.smallcaps}-mannopyranosyl-(1↔1)-6-*O*-benzyl-4-*O*-\[bis(benzyloxy)phosphoryl\]-2-deoxy-2-(9-fluorenylmethoxycarbonylamino)-α-[d]{.smallcaps}-glucopyranoside (**36**) {#sec3.1.1}

A solution of glycosyl donor **21** (613 mg, 1.03 mmol) and acceptor **10** (596 mg, 0.751 mmol) in dry CH~2~Cl~2~ (22 mL) was stirred with powdered activated 4 Å molecular sieves at room temperature (r.t.) for 1 h under an atmosphere of Ar. The mixture was cooled to 0 °C, and a solution of TMSOTf (9 μL, 52 μmol) in dry CH~2~Cl~2~ (450 μL of a stock solution prepared from 20 μL of TMSOTf in 1 mL of CH~2~Cl~2~) was added. The mixture was stirred at 0 °C for 30 min, and the reaction was quenched by addition of saturated aqueous (sat. aq.) NaHCO~3~ (2 mL). The mixture was warmed to r.t. and diluted with EtOAc (100 mL), the solids were removed by filtration over a pad of Celite, and the filtrate was concentrated. The residue was purified by MPLC (two successive columns: toluene--EtOAc, 4:1→1:1→0:1 followed by hexane--EtOAc, 3:1→2:1) to afford **36** (469 mg, 391 μmol, 52%), **39** (186 mg, 155 μmol, 20%), and **42** (44 mg, 37 μmol, 5%). Disaccharide **36**: *R*~*f*~ = 0.32 (hexane--EtOAc, 1:1); \[α\]~D~^20^ = +61 (*c* 0.9, CHCl~3~); ^1^H NMR (600 MHz, CDCl~3~) δ 7.76--7.75 (m, 2H, arom), 7.57--7.56 (m, 1H, arom.), 7.52--7.51 (m, 1H, arom), 7.45--7.23 (m, 24H, arom), 5.23 (t, 1H, ^3^*J*~3,2~ = ^3^*J*~3,4~ = 10.0 Hz, H-3), 5.20 (d, 1H, ^3^*J*~1,2~ = 3.5 Hz, H-1), 5.12 (s, 1H, H-1′), 5.03 (AB, 1H, ^2^*J* = 11.9 Hz, C*H*~2~Ph), 4.99--4.93 (m, 4H, OP(O)(OC*H*~2~Ph)~2~), 4.90 (d, 1H, ^3^*J*~NH,2~ = 9.6 Hz, N*H*), 4.82 (AB, 1H, ^2^*J* = 11.9 Hz, C*H*~2~Ph), 4.53--4.47 (m, 2H, H-4, C*H*~2~, Fmoc), 4.52 (AB, 1H, *J* = 11.7 Hz, C*H*~2~Ph), 4.44 (AB, 1H, *J* = 11.8 Hz, C*H*~2~Ph), 4.32 (t, 1H, ^3^*J*~4′,3′~ = ^3^*J*~4′,5′~ = 9.5 Hz, H-4′), 4.20 (t, 1H, ^3^*J* = 7.4 Hz, C*H*, Fmoc), 4.10--4.07 (m, 2H, H-2, C*H*~2~, Fmoc), 4.05 (dd, 1H, ^3^*J*~6a′,5′~ = 4.8 Hz, ^2^*J*~6a′,6b′~ = 10.3 Hz, H-6a′), 3.96 (t, 1H, ^3^*J*~6b′,5′~ = ^2^*J*~6b′,6a′~*=* 10.3 Hz, H-6b′), 3.79--3.76 (m, 2H, H-5, H-6a), 3.72--3.68 (m, 2H, H-3′, H-5′), 3.63 (dd, 1H, *J* = 5.9 Hz, 11.0 Hz, H-6b), 3.41 (s, 1H, H-2′), 3.40 (s, 3H, C*H*~3~, Me), 1.87 (s, 3H, C*H*~3~, Ac), 1.06 (s, 9H, 3×C*H*~3~, DTBS), 0.96 (s, 9H, 3×C*H*~3~, DTBS); ^13^C NMR (151 MHz, CDCl~3~) δ 171.58 (*C*O, Ac), 155.69 (*C*O, Fmoc), 143.79, 143.47, 141.23, 141.20 (4×*C*q, Fmoc), 138.73, 137.78 (2×Cq, CH~2~Ph), 135.46 (*C*q, ^3^*J*~C,P~ = 6.8 Hz, OP(O)(OC*H*~2~Ph)~2~), 135.39 (*C*q, ^3^*J*~C,P~ = 7.3 Hz, OP(O)(OC*H*~2~Ph)~2~), 128.72, 128.63, 128.36, 128.32, 128.01, 127.94, 127.79, 127.77, 127.70, 127.67, 127.61, 127.14, 125.12, 125.02, 120.00 (28×*C*H, arom), 93.70 (C-1′, ^1^*J*~C,H~ = 173 Hz), 93.07 (C-1, ^1^*J*~C,H~ = 172 Hz), 79.59 (C-2′), 77.84 (C-3′), 74.78 (C-4′), 74.03 (*C*H~2~Ph), 73.55 (*C*H~2~Ph), 73.49 (C-4, ^2^*J*~C4,P~ = 5.9 Hz), 71.35 (C-3), 70.63 (C-5, ^3^*J*~C5,P~ = 5.9 Hz), 69.70 (OP(O)(OC*H*~2~Ph)~2~), 69.66 (OP(O)(OC*H*~2~Ph)~2~), 69.19 (C-5′), 68.29 (C-6), 67.70 (*C*H~2~, Fmoc), 66.36 (C-6′), 59.68 (*C*H~3~, Me), 53.65 (C-2), 46.91 (*C*H, Fmoc), 27.41, 27.04 (6×*C*H~3~, DTBS), 22.56 (*C*q, DTBS), 20.70 (*C*H~3~, Ac), 19.79 (*C*q, DTBS); ^31^P NMR (243 MHz, CDCl~3~) δ −2.02; HRMS (ESI) *m*/*z* calcd for C~66~H~78~NO~16~PSi+H^+^ 1200.4900 \[M+H^+^\], found 1200.4900.

### 3-*O*-Benzyl-4,6-*O*-di-*tert*-butylsilylene-2-*O*-methyl-α-[d]{.smallcaps}-mannopyranosyl-(1↔1)-6-*O*-benzyl-4-*O*-\[bis(benzyloxy)phosphoryl\]-2-deoxy-2-(9-fluorenylmethoxycarbonylamino)-α-[d]{.smallcaps}-glucopyranoside (**46**) {#sec3.1.2}

A biphasic mixture of **36** (192 mg, 160 μmol) in THF (4 mL) and aq. hydroxylamine (50%, 4 mL) was vigorously stirred at 0 °C for 48 h. The mixture was diluted with EtOAc (50 mL) and washed with aq. citric acid (0.25 M, 70 mL), sat. aq. NaHCO~3~ (50 mL), and brine (50 mL). The organic layer was dried over MgSO~4~, filtered, and concentrated. The residue was purified by HPLC (two successive columns: toluene--EtOAc, 1:1, and hexane--EtOAc, 3:1→1:1, Column A) to afford **46**, unreacted **36** (56%), **47**, and **48**. The recovered **36** (108 mg, 90 μmol) was subjected to two additional reaction cycles to afford, after isolation by HPLC, compounds **46** (overall yield: 99 mg, 85 μmol, 53%), **47** (4 mg, 3.5 μmol, 2%), and **48** (16 mg, 15 μmol, 9%). Disaccharide **46**: *R*~*f*~ = 0.60 (toluene--EtOAc, 1:1); \[α\]~D~^20^ = +72 (*c* 1.0, CHCl~3~); ^1^H NMR (600 MHz, CDCl~3~) δ 7.76--7.75 (m, 2H, arom), 7.61--7.58 (m, 2H, arom), 7.41--7.23 (m, 24H, arom), 5.25 (s, 1H, H-1), 5.09--4.99 (m, 6H, H-1′, C*H*~2~Ph, OP(O)(OCH~2~Ph)~2~), 4.79--4.74 (m, 2H, C*H*~2~Ph, N*H*), 4.63--4.56 (m, 1H, C*H*~2~, Fmoc), 4.47 (s, 2H, C*H*~2~Ph), 4.32 (t, 1H, *J* = 9.4 Hz, H-4′), 4.28--4.22 (m, 2H, H-4, C*H*, Fmoc), 4.19--4.13 (m, 1H, C*H*~2~, Fmoc), 4.07--4.05 (m, 1H, H-6a′), 3.98--3.88 (m, 1H, H-2), 3.95 (t, 1H, *J* = 10.4 Hz, H-6b′), 3.81--3.75 (m, 1H, H-3), 3.71 (td, *J* = 4.8 Hz, *J* = 10.1 Hz, H-5′), 3.69--3.60 (m, 3H, H-3′, H-5, H-6a), 3.55 (dd, *J* = 5.2 Hz, *J* = 10.9 Hz, H-6b), 3.40 (s, 3H, C*H*~3~, Me), 3.36 (s, 1H, H-2′), 1.06 (s, 9H, 3×C*H*~3~, DTBS), 0.95 (s, 9H, 3×C*H*~3~, DTBS); ^13^C NMR (151 MHz, CDCl~3~) δ 143.87, 143.78, 141.27, 141.25 (4×*C*q, Fmoc), 138.84, 137.77 (2×*C*q, CH~2~Ph), 135.28, 135.24 (2×*C*q, OP(O)(OCH~2~Ph)~2~), 128.91, 128.78, 128.73, 128.65, 128.36, 128.24, 127.93, 127.84, 127.73, 127.71, 127.67, 127.58, 127.17, 127.08, 125.32, 125.19, 119.96, 119.95 (28×*C*H, arom), 93.81 (C-1′), 93.48 (C-1), 79.81 (C-2′), 77.69 (C-3′), 74.83 (C-4′), 73.84, 73.63 (2×*C*H~2~Ph), 70.98 (C-3), 70.49, 70.32 (C-5, *J*~C,P~ =8.9 Hz, OP(O)(OCH~2~Ph)~2~, *J*~C,P~ = 5.7 Hz,), 70.04 (OP(O)(OCH~2~Ph)~2~, ^2^*J*~C,P~ = 5.6 Hz), 69.20 (C-5′), 68.36 (C-6), 67.59 (*C*H~2~, Fmoc), 66.40 (C-6′), 59.61 (*C*H~3~, Me), 54.79 (C-2), 47.14 (*C*H~2~, Fmoc), 27.46, 27.06 (6×*C*H~3~, DTBS), 22.59, 19.81 (2×*C*q, DTBS); ^31^P NMR (243 MHz, CDCl~3~) δ 0.43; HRMS (ESI) *m*/*z* calcd for C~64~H~767~NO~15~PSi+H^+^ 1158.4795 \[M+H^+^\], found 1158.4790.

### 3-*O*-Benzyl-4,6-*O*-di-*tert*-butylsilylene-2-*O*-methyl-α-[d]{.smallcaps}-mannopyranosyl-(1↔1)-6-*O*-benzyl-4-*O*-\[bis(benzyloxy)phosphoryl\]-2-deoxy-2-(9-fluorenylmethoxycarbonylamino)-3-*O*-\[(*R*)-3-(tetradecanoyloxy)tetradecanoyl\]-α-[d]{.smallcaps}-glucopyranoside (**52**) {#sec3.1.3}

To a stirred solution of **46** (95 mg, 82 μmol) in dry CH~2~Cl~2~ (500 μL) were added solutions of **49** (37 mg, 82 μmol) in dry CH~2~Cl~2~ (200 μL), DMAP (1 mg, 8 μmol) in dry CH~2~Cl~2~ (90 μL of a stock solution 11 mg of DMAP in 1 mL of CH~2~Cl~2~), and DIC (10 mg, 82 μmol) in dry CH~2~Cl~2~ (150 μL) at 0 °C, and the mixture was stirred for 2.5 h. Then additional portions of **49** (37 mg, 82 μmol) and DIC (10 mg, 82 μmol) were added, and the mixture was stirred for 4.5 h at 0 °C, diluted with EtOAc (50 mL), and washed with aq. citric acid (0.25 M, 50 mL), sat. aq. NaHCO~3~ (50 mL), and brine (50 mL). The organic layer was dried over MgSO~4~, filtered, and concentrated. The residue was purified by HPLC (hexane--EtOAc, 5:1→3:1) to afford **52** (109 mg, 68 μmol, 83%) as a colorless syrup. Fractions containing byproducts were purified by HPLC (hexane--EtOAc, 4:1→3:1, Column B) to afford **53** (12 mg, 9 μmol, 11%) and **54** (3 mg, 2.2 μmol, 3%). Compound **52**: *R*~*f*~ = 0.66 (toluene--EtOAc, 1:1); \[α\]~D~^20^ = +44 (*c* 1.0, CHCl~3~); ^1^H NMR (600 MHz, CDCl~3~) δ 7.75--7.74 (m, 2H, arom), 7.59--7.58 (m, 1H, arom), 7.54--7.53 (m, 1H, arom), 7.45--7.43 (m, 2H, arom), 7.40--7.23 (m, 22H, arom), 5.32 (d, 1H, ^3^*J*~NH,2~ = 8.5 Hz, N*H*), 5.27 (d, 1H, ^3^*J*~1,2~ = 3.0 Hz, H-1), 5.24 (t, 1H, ^3^*J*~3,4~ = ^3^*J*~3,2~ = 10.0 Hz, H-3), 5.20--5.16 (m, 1H, β^Myr^-C*H*), 5.11 (s, 1H, H-1′), 5.04 (AB, 1H, ^2^*J* = 11.9 Hz, C*H*~2~Ph), 4.98--4.94 (m, 4H, OP(O)(OC*H*~2~Ph)~2~), 4.81 (AB, 1H, ^2^*J* = 11.8 Hz, C*H*~2~Ph), 4.50 (AB, 1H, ^2^*J* = 11.9 Hz, C*H*~2~Ph), 4.47--4.41 (m, 2H, H-4, C*H*~2~, Fmoc), 4.41 (AB, 1H, ^2^*J* = 11.9 Hz, C*H*~2~Ph), 4.32 (t, 1H, ^3^*J*~4′,5′~ = ^3^*J*~4′,3′~ = 9.5 Hz, H-4′), 4.18 (t, 1H, *J* = 7.4 Hz, C*H*, Fmoc), 4.15--4.12 (m, 1H, C*H*~2~, Fmoc), 4.08--4.04 (m, 2H, H-2, H-6a′), 3.96 (t, 1H, ^3^*J*~6b′,5′~ = ^2^*J*~6b′,6a′~ =10.2 Hz, H-6b′), 3.80--3.73 (m, 4H, H-3′, H-5′, H-5, H-6a), 3.61 (dd, 1H, *J* = 6.0 Hz, *J* = 11.1 Hz, H-6b), 3.39 (s, 1H, H-2′), 3.38 (s, 3H, C*H*~3~, Me), 2.49 (dd, 1H, ^3^*J* = 8.3 Hz, ^2^*J* = 16.1 Hz, α^Myr^-C*H*~2~), 2.40 (dd, 1H, ^3^*J* = 4.4 Hz, ^2^*J* = 16.1 Hz, α^Myr^-C*H*~2~), 2.19--2.10 (m, 2H, α^Myr^-C*H*~2~), 1.54--1.50 (m, 2H, β^Myr^-C*H*~2~), 1.42--1.35 (m, 2H, γ^Myr^-C*H*~2~), 1.30--1.06 (m, 38H, 19×C*H*~2~), 1.05 (s, 9H, 3×CH~3~, DTBS), 0.94 (s, 9H, 3×CH~3~, DTBS), 0.88 (t, 6H, *J* = 7.1 Hz, 2×ω^Myr^-C*H*~3~); ^13^C NMR (151 MHz, CDCl~3~) δ 173.23, 171.16 (2×*C*O), 155.91 (*C*O, Fmoc), 143.74, 143.66, 141.22, 141.19 (4×*C*q, Fmoc), 138.83, 137.87 (2×*C*q, CH~2~Ph), 135.55, 135.51 (2×*C*q, OP(O)(OCH~2~Ph)~2~), 128.71, 128.64, 128.38, 128.33, 128.16, 128.04, 127.94, 127.80, 127.68, 127.66, 127.62, 127.21, 127.18, 125.29, 125.18, 119.95 (28×*C*H, arom), 94.02 (C-1′), 93.25 (C-1), 79.76 (C-2′), 78.15 (C-3′), 74.84 (C-4′), 74.23 (*C*H~2~Ph), 73.65 (C-4, ^2^*J*~C4,P~ = 5.7 Hz), 73.51 (*C*H~2~Ph), 71.21 (C-3), 70.69 (C-5, ^3^*J*~C5,P~ = 5.3 Hz), 69.79 (β^Myr^-*C*H or C-5′), 69.78 (OP(O)(O*C*H~2~Ph)~2~, ^2^*J*~C,P~ = 6.5 Hz), 69.74 (OP(O)(O*C*H~2~Ph)~2~, ^2^*J*~C,P~ = 6.1 Hz), 69.21 (β^Myr^-*C*H or C-5′), 68.36 (C-6), 67.92 (*C*H~2~, NHFmoc), 66.40 (C-6′), 59.70 (*C*H~3~, Me), 53.80 (C-2), 47.01 (*C*H, Fmoc), 38.96 (α^Myr^-*C*H~2~), 34.37 (α^Myr^-*C*H~2~), 34.09 (γ^Myr^-*C*H~2~), 31.91, 29.68, 29.65, 29.62, 29.52, 29.49, 29.38, 29.35, 29.30, 29.17, 27.46, 27.07, 24.98, 22.68 (20×*C*H~2~, 6×*C*H~3~, DTBS), 22.59, 19.79 (2×*C*q, DTBS), 14.10 (2×ω^Myr^-*C*H~3~); ^31^P NMR (243 MHz, CDCl~3~) δ −1.71; HRMS (ESI) *m*/*z* calcd for C~92~H~128~NO~18~PSi+Na^+^ 1616.8513 \[M+Na^+^\], found 1616.8526.

### 3-*O*-Benzyl-4,6-*O*-di-*tert*-butylsilylene-2-*O*-methyl-α-[d]{.smallcaps}-mannopyranosyl-(1↔1)-6-*O*-benzyl-4-*O*-\[bis(benzyloxy)phosphoryl\]-2-deoxy-2-\[(*R*)-3-(dodecanoyloxy)tetradecanonylamino\]-3-*O*-\[(*R*)-3-(tetradecanoyloxy)tetradecanoyl\]-α-[d]{.smallcaps}-glucopyranoside (**55**) {#sec3.1.4}

To a stirred solution of **52** (104 mg, 65 μmol) in dry CH~2~Cl~2~ (1 mL) was added DBU (20 μL, 134 μmol) at 0 °C, and the stirring was continued for 1.5 h at r.t. The mixture was diluted with EtOAc (25 mL) and washed with aq. citric acid (0.25 M, 25 mL), sat. aq. NaHCO~3~ (25 mL), and brine (25 mL). The organic phase was dried over MgSO~4~, filtered, and concentrated. The mixture was purified by silica gel chromatography (hexane--EtOAc, 3:1 (0.1% Et~3~N)→1:1 (0.1% Et~3~N) to afford the crude amine (78 mg), *R*~*f*~ = 0.28 (hexane--EtOAc, 1:1). To a stirred solution of the intermediate amine (78 mg) in dry CHCl~3~ (400 μL) were added a solution of **50** (29 mg, 68 μmol) in dry CHCl~3~ (150 μL) and a solution of EDC·HCl (13 mg, 68 μmol) in dry CHCl~3~ (200 μL) at r.t. The mixture was stirred for 1.5 h, and then additional amounts of **50** (29 mg, 68 μmol) and EDC·HCl (13 mg, 68 μmol) were added. The mixture was stirred for 3 h, diluted with CHCl~3~ (30 mL), and washed with water--brine (1:1, 50 mL). The organic phase was dried over MgSO~4~, filtered, and concentrated. The residue was purified by MPLC (hexane--EtOAc, 4:1→3:1) to afford **55** (91 mg, 51 μmol, 78% over two steps) as a colorless syrup: *R*~*f*~ = 0.44 (hexane--EtOAc, 2:1); \[α\]~D~^20^ = +35 (*c* 1.0, CHCl~3~); ^1^H NMR (600 MHz, CDCl~3~) δ 7.43--7.42 (m, 2H, CH~2~Ph), 7.35--7.22 (m, 18H, CH~2~Ph), 6.10 (d, 1H, ^3^*J*~NH,2~ = 7.9 Hz, N*H*), 5.23--5.12 (m, 2H, 2×β^Myr^-C*H*), 5.20 (d, 1H, ^3^*J*~1,2~ = 3.6 Hz, H-1), 5.17 (dd, ^3^*J*~3,4~ = 9.0 Hz, ^3^*J*~3,2~ = 11.1 Hz, H-3), 5.08 (d, 1H, ^3^*J*~1′,2′~ = 1.5 Hz, H-1′), 5.01 (AB, 1H, ^2^*J* = 11.9 Hz, C*H*~2~Ph), 4.96--4.92 (m, 4H, 2×C*H*~2~, OP(O)(OC*H*~2~Ph)~2~), 4.77 (AB, 1H, ^2^*J* = 11.9 Hz, C*H*~2~Ph), 4.48 (AB, 1H, ^2^*J* = 11.8 Hz, C*H*~2~Ph), 4.39 (AB, 1H, ^2^*J* = 11.8 Hz, C*H*~2~Ph), 4.38--4.35 (m, 1H, H-4), 4.30 (t, ^3^*J*~4′,3′~ = ^3^*J*~4′,5′~ = 9.5 Hz, H-4′), 4.25 (ddd, 1H, ^3^*J*~2,1~ = 3.6 Hz, ^3^*J*~2,NH~ = 7.8 Hz, ^3^*J*~2,3~ = 11.2 Hz, H-2), 4.03 (dd, 1H, ^3^*J*~6a′,5′~ = 5.0 Hz, ^2^*J*~6a′,6b′~ = 10.3 Hz, H-6a′), 3.93 (t, 1H, ^3^*J*~6b′,5′~ = ^2^*J*~6b′,6a′~ = 10.4 Hz, H-6b′), 3.76--3.74 (m, 2H, H-5, H-6a), 3.71 (dd, 1H, ^3^*J*~3′,2′~ = 3.3 Hz, ^3^*J*~3′,4′~ = 9.6 Hz, H-3′), 3.63 (td, 1H, ^3^*J*~5′,6a′~ = 4.9 Hz, ^3^*J*~5′,4′~ = ^3^*J*~5′,6b′~ = 9.9 Hz, H-5′), 3.56 (dd, 1H, *J* = 6.1 Hz, *J* = 10.8 Hz, H-6b), 3.39 (dd, 1H, ^3^*J*~2′,1′~ = 1.6 Hz, ^3^*J*~2′,3′~ = 3.2 Hz, H-2′), 3.34 (s, 3H, C*H*~3~, Me), 2.48--2.32 (m, 4H, 2×α^Myr^-C*H*~2~), 2.28--2.19 (m, 4H, α^Myr^-C*H*~2~, α^Lau^-C*H*~2~), 1.60--1.46 (m, 8H, 2×γ^Myr^-C*H*~2~, β^Myr^-C*H*~2~, β^Lau^-C*H*~2~), 1.28--1.23 (m, 72H, 36×C*H*~2~, fatty acids), 1.07 (s, 9H, 3×C*H*~3~, DTBS), 1.01 (s, 9H, 3×C*H*~3~, DTBS), 0.89--0.86 (m, 12H, 3×ω^Myr^-C*H*~3~, ω^Lau^-C*H*~3~); ^13^C NMR (151 MHz, CDCl~3~) δ 173.53, 173.26, 171.26, 169.79 (4×*C*O), 138.90, 137.89 (2×*C*q, CH~2~Ph) 135.56, 135.51 (2×*C*q, OP(O)(OCH~2~Ph)~2~) 128.71, 128.63, 128.36, 128.31, 128.18, 128.05, 127.85, 127.63, 127.62, 127.59 (20×*C*H, CH~2~Ph), 93.80 (C-1′), 93.11 (C-1), 79.74 (C-2′), 78.25 (C-3′), 74.65 (C-4′), 74.11 (*C*H~2~Ph), 73.86 (C-4), 73.47 (*C*H~2~Ph), 70.90, 70.76 (C-3, C-5), 70.09, 70.01 (2×β^Myr^-*C*H), 69.77, 69.75, 69.74, 69.72 (2×*C*H~2~, OP(O)(O*C*H~2~Ph)~2~), 69.33 (C-5′), 68.44 (C-6), 66.36 (C-6′), 59.57 (*C*H~3~, Me), 51.66 (C-2), 40.95, 39.29 (2×α^Myr^-*C*H~2~), 34.58, 34.46 (α^Myr^*C*H~2~, α^Lau^*C*H~2~, 2×γ^Myr^*C*H~2~), 31.93, 31.92, 29.72, 29.69, 29.66, 29.62, 29.57, 29.52, 29.39, 29.36, 29.25, 29.22, 25.26, 25.19, 25.05, 25.04, 22.68 (38×*C*H~2~) 27.53, 27.29 (6×CH~3~, DTBS), 22.64, 19.87 (2×*C*q, DTBS), 14.09 (3×ω^Myr^-*C*H~3~, ω^Lau^-*C*H~3~); ^31^P NMR (242.97 MHz, CDCl~3~) δ −1.67; HRMS (ESI) *m*/*z* calcd for C~103~H~166~NO~19~PSi+Na^+^ 1780.1453 \[M+Na^+^\], found 1780.1430.

### 3-*O*-Benzyl-2-*O*-methyl-α-[d]{.smallcaps}-mannopyranosyl-(1↔1)-6-*O*-benzyl-4-*O*-\[bis(benzyloxy)phosphoryl\]-2-deoxy-2-\[(*R*)-3-(dodecanoyloxy)tetradecanoylamino\]-3-*O*-\[(*R*)-3-(tetradecanoyloxy)tetradecanoyl\]-α-[d]{.smallcaps}-glucopyranoside (**56**) {#sec3.1.5}

To a stirred solution of **55** (91 mg, 51 μmol) in dry THF (3 mL) in a PTFE vial was added a solution of HF·Py (70%, 50 μL) at 0 °C. The mixture was stirred for 30 min at r.t., diluted with EtOAc (20 mL), and washed with sat. aq. NaHCO~3~ (30 mL) and brine (30 mL). The organic phase was dried over Na~2~SO~4~, filtered, and concentrated. The residue was purified by silica gel chromatography (toluene--EtOAc, 3:1) to afford **56** (78 mg, 47 μmol, 92%): *R*~*f*~ = 0.22 (toluene--EtOAc, 1:1); \[α\]~D~^20^ = +41 (*c* 1.0, CHCl~3~); ^1^H NMR (600 MHz, CDCl~3~) δ 7.43--7.22 (m, 20H, CH~2~Ph), 6.34 (d, 1H, ^3^*J*~NH,2~ = 8.2 Hz, N*H*), 5.26 (d, 1H, ^3^*J*~1,2~ = 3.7 Hz, H-1), 5.22 (dd, 1H, ^3^*J*~3,4~ = 9.1 Hz, ^3^*J*~3,2~ = 11.0 Hz, H-3), 5.14--5.10 (m, 1H, β^Myr^-C*H*), 5.13 (d, 1H, ^3^*J*~1′,2′~ = 1.6 Hz, H-1′), 5.05--5.01 (m, 1H, β^Myr^-C*H*), 4.97--4.93 (m, 4H, 2×C*H*~2~, OP(O)(OC*H*~2~Ph)~2~), 4.79 (AB, 1H, ^2^*J* = 11.6 Hz, C*H*~2~Ph), 4.73 (AB, 1H, ^2^*J* = 11.7 Hz, C*H*~2~Ph), 4.49 (AB, 1H, ^2^*J* = 11.8 Hz, C*H*~2~Ph), 4.42 (q, 1H, ^3^*J*~4,3~ = ^3^*J*~4,5~ = ^3^*J*~H,P~ = 9.2 Hz, H-4), 4.40 (AB, 1H, ^2^*J* = 11.9 Hz, C*H*~2~Ph), 4.26 (ddd, 1H, ^3^*J*~1,2~ = 3.5 Hz, ^3^*J*~2,NH~ = 8.0 Hz, ^3^*J*~2,3~ = 11.2 Hz, H-2), 3.92--3.88 (m, 1H, H-4′), 3.84--3.79 (m, 2H, H-3′, H-6a′), 3.76--3.74 (m, 3H, H-5, H-6a, H-6b′), 3.60--3.56 (m, 2H, H-5′, H-6b), 3.30 (s, 3H, C*H*~3~, Me), 3.30--3.28 (m, 1H, H-2′), 2.70 (s, 1H, OH), 2.48--2.42 (m, 3H, α^Myr^-C*H*~2~), 2.39 (dd, 1H, *J* = 6.2 Hz, *J* = 15.3 Hz, α^Myr^-C*H*~2~), 2.34--2.26 (m, 2H, α^Lau^-C*H*~2~), 2.23--2.20 (m, 2H, α^Myr^-C*H*~2~), 1.65--1.46 (m, 8H, 2×γ^Myr^C*H*~2~, β^Myr^C*H*~2~, β^Lau^C*H*~2~), 1.31--1.21 (m, 72H, 36×C*H*~2~), 0.89--0.86 (m, 12H, 3×ω^Myr^-C*H*~3~, ω^Lau^-C*H*~3~); ^13^C NMR (151 MHz, CDCl~3~) δ 174.65, 173.48, 171.15, 170.08 (4×CO), 138.10, 137.87 (2×Cq, CH~2~Ph), 135.47 (2×Cq, OP(O)(OCH~2~Ph)~2~), 128.72, 128.63, 128.60, 128.31, 128.17, 128.04, 128.01, 127.63, 127.59 (20×*C*H, CH~2~Ph), 93.14 (C-1′), 92.56 (C-1), 78.78 (C-3′), 77.38 (C-2′), 73.76 (C-4, C-5′), 73.48, 72.76 (2×*C*H~2~Ph), 71.33 (β^Myr^-*C*H), 71.02 (C-3), 70.62 (C-5, ^3^*J*~C5,P~ = 5.0 Hz), 70.01 (β^Myr^-*C*H), 69.82 (2×*C*H~2~, OP(O)(O*C*H~2~Ph)~2~), 68.42 (C-6), 67.84 (C-4′), 63.04 (C-6′), 59.03 (*C*H~3~, Me), 51.70 (C-2), 41.50, 39.09 (2×α^Myr^-*C*H~2~), 34.74, 34.60, 34.41, 34.23 (α^Myr^*C*H~2~, α^Lau^*C*H~2~, 2×γ^Myr^*C*H~2~), 31.92, 31.91, 29.70, 29.68, 29.65, 29.61, 29.58, 29.54, 29.47, 29.43, 29.37, 29.34, 29.20, 29.18, 25.28, 25.17, 25.01, 24.99, 22.67 (38×*C*H~2~), 14.08 (3×ω^Myr^-*C*H~3~, ω^Lau^-*C*H~3~); ^31^P NMR (243 MHz, CDCl~3~) δ −1.80; HRMS (ESI) *m*/*z* calcd for C~95~H~150~NO~19~P+Na^+^ 1663.0432 \[M+Na^+^\], found 1663.0424.

### 3-*O*-Benzyl-4-*O*-\[(*R*)-3-(dodecanoyloxy)tetradecanoyl\]-2-*O*-methyl-α-[d]{.smallcaps}-mannopyranosyl-(1↔1)-6-*O*-benzyl-4-*O*-\[bis(benzyloxy)phosphoryl\]-2-deoxy-2-\[(*R*)-3-(dodecanoyloxy)tetradecanoylamino\]-3-*O*-\[(*R*)-3-(tetradecanoyloxy)tetradecanoyl\]-α-[d]{.smallcaps}-glucopyranoside (**57**) {#sec3.1.6}

To a stirred solution of **56** (21 mg, 13 μmol) and DMAP (0.15 mg, 1.3 μmol) in dry CH~2~Cl~2~ (500 μL) was added a solution of fatty acid **50** (6.5 mg, 15 μmol) in CH~2~Cl~2~ (50 μL of a stock solution prepared from 26 mg of **50** in 200 μL of CH~2~Cl~2~). The mixture was cooled to 0 °C, and DIC (1.9 mg, 15.4 μmol) from a 50 mg/mL stock solution in toluene was added dropwise over a period of 1 h. Then additional amounts of **50** (1.3 mg, 3.1 μmol) and DIC (0.4 mg, 0.3 μmol) from the indicated stock solutions were successively added (DIC was added dropwise over 30 min) at 0 °C. The mixture was diluted with EtOAc (20 mL) and washed with aq. 2 M HCl (20 mL), aq. sat. NaHCO~3~ (20 mL), and brine (20 mL). The organic layer was dried over Na~2~SO~4~, filtered, and concentrated. The residue was purified by HPLC (two consecutive columns: toluene--EtOAc, 3:1→2:1, and hexane--EtOAc, 3:1→1:1, column B) to afford **57** (13.5 mg, 6.6 μmol, 51%) as a syrup. Fractions containing byproduct **59** were purified by HPLC (hexane--EtOAc, 5:1→3:1) to afford **59** (7.6 mg, 3.1 μmol, 24%) as a syrup. Compound **57**: *R*~*f*~ = 0.27 (hexane--EtOAc, 1:1); \[α\]~D~^20^ = +68 (*c* 1.0, CHCl~3~); ^1^H NMR (600 MHz, CDCl~3~) δ 7.38--7.21 (m, 20H, CH~2~Ph), 6.37 (d, 1H, ^3^*J*~NH,2~ = 8.2 Hz, N*H*), 5.24--5.15 (m, 5H, H-1, H-3, H-4′, 2×β^Myr^-C*H*), 5.12 (d, 1H, ^3^*J*~1′,2′~ = 2.0 Hz, H-1′), 5.07--5.03 (m, 1H, β^Myr^-C*H*), 4.97--4.94 (m, 4H, OP(O)(OC*H*~2~Ph)~2~), 4.69 (AB, 1H, ^2^*J* = 11.9 Hz, C*H*~2~Ph), 4.64 (AB, 1H, ^2^*J* = 12.1 Hz, C*H*~2~Ph), 4.48 (AB, 1H, ^2^*J* = 11.8 Hz, C*H*~2~Ph), 4.42 (ddd, 1H, ^3^*J*~4,3~ = ^3^*J*~4,5~ = ^3^*J*~H,P~ = 9.3 Hz, H-4), 4.40 (AB, 1H, ^2^*J* = 11.9 Hz, C*H*~2~Ph), 4.24 (ddd, 1H, ^3^*J*~2,1~ = 3.6 Hz, ^3^*J*~2,NH~ = 8.1 Hz, ^3^*J*~2,3~ = 11.1 Hz, H-2), 3.94 (dd, 1H, ^3^*J*~3′,2′~ = 3.1 Hz, ^3^*J*~3′,4′~ = 9.4 Hz, H-3′), 3.75--3.72 (m, 2H, H-5, H-6a), 3.62--3.55 (m, 4H, H-5′, H-6a′, H-6b′, H-6b), 3.30--3.29 (m, 1H, H-2′), 3.29 (s, 3H, C*H*~3~, Me), 2.60 (dd, 1H, *J* = 7.6 Hz, 15.5 Hz, α^Myr^-C*H*~2~), 2.54--2.47 (m, 3H, α^Myr^-C*H*~2~), 2.44 (dd, 1H, *J* = 7.2 Hz, 15.0 Hz, α^Myr^-C*H*~2~), 2.37 (dd, 1H, *J* = 5.6 Hz, 15.1 Hz, α^Myr^-C*H*~2~), 2.30--2.27 (m, 2H, α-C*H*~2~), 2.24--2.19 (m, 4H, 2×α-C*H*~2~), 1.62--1.48 (m, 12H, β^Myr^-C*H*~2~, 2×β^Lau^-C*H*~2~, 3×ω^Myr^-C*H*~2~), 1.30--1.22 (m, 106H, 53×C*H*~2~), 0.89--0.86 (m, 18H, 4×ω^Myr^-C*H*~3~, 2×ω^Lau^-C*H*~3~); ^13^C NMR (151 MHz, CDCl~3~) δ 173.64, 173.40, 173.10, 171.43, 169.93, 169.88 (6×*C*O), 138.01, 137.88 (2×*C*q, CH~2~Ph), 135.55, 135.51 (2×*C*q, OP(O)(OCH~2~Ph)~2~), 128.71, 128.64, 128.53, 128.32, 128.12, 128.11, 128.04, 127.93, 127.65, 127.59 (20×*C*H, CH~2~Ph), 94.03 (C-1′), 93.51 (C-1), 77.81 (C-2′), 75.89 (C-3′), 73.67 (C-4, ^2^*J*~C4,P~ = 5.8 Hz), 73.49 (*C*H~2~Ph), 72.74 (C-5′), 72.52 (*C*H~2~Ph), 71.09 (C-3), 70.84 (β^Myr^-*C*H), 70.69 (C-5, ^3^*J*~C5,P~ = 5.3 Hz), 69.95, 69.88 (2×β^Myr^-*C*H), 69.77, 69.73 (2×*C*H~2~, OP(O)(O*C*H~2~Ph)~2~), 68.36 (C-6), 68.35 (C-4′), 61.71 (C-6′), 59.10 (*C*H~3~, Me), 51.81 (C-2), 41.38, 39.16, 39.02 (3×α^Myr^-*C*H~2~), 34.60, 34.53, 34.44, 34.28, 34.05 (α^Myr^-*C*H~2~, 2×α^Lau^-*C*H~2~, 3×γ^Myr^-*C*H~2~), 31.93, 29.73, 29.70, 29.67, 29.62, 29.60, 29.57, 29.55, 29.54, 29.52, 29.48, 29.42, 29.39, 29.37, 29.36, 29.33, 29.28, 29.20, 25.36, 25.17, 25.10, 25.01, 22.69 (56×*C*H~2~), 14.10 (4×ω^Myr^-*C*H~3~, 2×ω^Lau^-*C*H~3~); ^31^P NMR (243 MHz, CDCl~3~) δ −1.71; HRMS (ESI) *m*/*z* calcd for C~121~H~198~NO~22~P+Na^+^ 2071.4035 \[M+Na^+^\], found 2071.4036.

### 3-*O*-Benzyl-6-*O*-\[bis(benzyloxy)phosphoryl\]-4-*O*-\[(*R*)-3-(dodecanoyloxy)tetradecanoyl\]-2-*O*-methyl-α-mannopyranosyl-(1↔1)-6-*O*-benzyl-4-*O*-\[bis(benzyloxy)phophoryl\]-2-deoxy-2\[(*R*)-3-(dodecanoyloxy)tetradecanoylamino\]-3-*O*-\[(*R*)-3-(tetradecanoyloxy)tetradecanoyl\]-α-[d]{.smallcaps}-glucopyranoside (**61**) {#sec3.1.7}

To a stirred solution of **57** (11 mg, 6 μmol) and dibenzyl *N*,*N*-diisopropylphosphoramidite (10 μL, 25 μmol, 90%) in dry CH~2~Cl~2~ (400 μL) was added a solution of 1*H*-tetrazole (54 μL, 24 μmol, 0.45 M in CH~3~CN) under an atmosphere of Ar. The mixture was stirred for 1 h and then cooled to −78 °C, and a solution of *m*CPBA (7 mg, 70%) in CH~2~Cl~2~ (54 μL) was added. After being stirred for 45 min, the reaction was quenched by addition of Et~3~N (5 μL), and then the mixture was warmed to r.t., diluted with CH~2~Cl~2~ (10 mL), and washed with sat. aq. NaHCO~3~ (5 mL) and brine (5 mL). The organic phase was dried over Na~2~SO~4~ and concentrated. The residue was purified by HPLC (two consecutive columns: toluene--EtOAc, 10:1→5:1→1:1 followed by hexane--EtOAc, 2:1→1:1, column B) to afford **61** (11 mg, 5 μmol, 89%) as a syrup: *R*~*f*~ = 0.53 (hexane--EtOAc, 1:1); \[α\]~D~^20^ = +31 (*c* 1.0, CHCl~3~); ^1^H NMR (600 MHz, CDCl~3~) δ 7.38--7.21 (m, 30H, CH~2~Ph), 6.46 (d, 1H, ^3^*J*~NH,2~ = 8.3 Hz, N*H*), 5.30 (t, 1H, ^3^*J*~4′,5′~ = ^3^*J*~4′,3′~ = 9.8 Hz, H-4′), 5.23--5.16 (m, 3H, H-3, 2×β^Myr^-C*H*), 5.15 (d, 1H, ^3^*J*~1,2~ = 3.7 Hz, H-1), 5.10 (d, 1H, ^3^*J*~1′,2′~ = 2.0 Hz, H-1′), 5.10--5.06 (m, 1H, β^Myr^-C*H*), 5.03--4.93 (m, 8H, 2×OP(O)(OC*H*~2~Ph)~2~), 4.67 (AB, 1H, ^2^*J* = 12.1 Hz, C*H*~2~Ph), 4.63 (AB, 1H, ^2^*J* = 12.1 Hz, C*H*~2~Ph), 4.45 (AB, 1H, ^2^*J* = 11.8 Hz, C*H*~2~Ph), 4.43--4.39 (m, 1H, H-4), 4.38 (AB, 1H, ^2^*J* = 11.9 Hz, C*H*~2~Ph), 4.30--4.26 (m, 1H, H-2), 4.07--4.04 (m, 2H, H-6a′, H-6b′), 4.01 (dd, 1H, ^3^*J*~3′,2′~ = 3.0 Hz, ^3^*J*~3′,4′~ = 9.6 Hz, H-4′), 3.89--3.86 (m, 1H, H-5′), 3.74 (dd, 1H, ^3^*J*~6a,5~ = 1.7 Hz, ^2^*J*~6a,6b~ = 10.8 Hz, H-6a), 3.72--3.69 (m, 1H, H-5), 3.56 (dd, 1H, ^3^*J*~6b,5~ = 5.9 Hz, ^2^*J*~6b,6a~ = 10.8 Hz, H-6b), 3.28 (t, 1H, *J* = 2.6 Hz, H-2′), 3.23 (s, 3H, C*H*~3~, Me), 2.58--2.52 (m, 3H, α^Myr^-C*H*~2~), 2.48--2.44 (m, 2H, α^Myr^-C*H*~2~), 2.41--2.38 (m, 1H, α^Myr^-C*H*~2~), 2.34--2.24 (m, 2H, α^Lau^-C*H*~2~), 2.20--2.16 (m, 4H, α^Lau^-C*H*~2~, α^Myr^-C*H*~2~), 1.61--1.49 (m, 12H, β^Myr^-C*H*~2~, 2×β^Lau^-C*H2*, 3×γ^Myr^-C*H*~2~), 1.29--1.22 (m, 106H, 53×C*H*~2~), 0.89--0.86 (m, 18H, 4×ω^Myr^-C*H*~3~, 2×ω^Lau^-C*H*~3~); ^13^C NMR (151 MHz, CDCl~3~) δ 173.89, 173.25, 172.94, 171.20, 169.77, 169.07 (6×*C*O), 137.99, 137.85 (2×*C*q, CH~2~Ph), 135.98, 135.94, 135.56, 135.51 (4×*C*q, OP(O)(OCH~2~Ph)~2~), 128.69, 128.63, 128.54, 128.46, 128.44, 128.30, 128.28, 128.14, 128.02, 127.96, 127.92, 127.88, 127.64, 127.60 (30×*C*H, CH~2~Ph), 93.36 (C-1′), 93.18 (C-1), 77.55 (C-2′), 75.96 (C-3′), 73.69 (C-4, ^2^*J*~C4,P~ = 6.1 Hz), 73.49, 72.47 (2×*C*H~2~, Ph), 71.24, 70.96, 70.66, 70.60, 69.82, 69.76 (C-3, C-5, C-5′, β^Myr^-*C*H, 2×β^Lau^-*C*H), 69.78, 69.74, 69.70, 69.32 (4×*C*H~2~, OP(O)(O*C*H~2~Ph)~2~), 68.48 (C-6), 67.50 (C-4′), 66.15 (C-6′), 59.02 (*C*H~3~, Me), 51.44 (C-2), 41.56, 38.96, 38.77 (3×α^Myr^-*C*H~2~), 34.77, 34.55, 34.41, 34.20, 34.00 (α^Myr^-*C*H~2~, 2×α^Lau^-*C*H~2~, 3×γ^Myr^-*C*H~2~), 31.94, 31.92, 29.75, 29.73, 29.69, 29.67, 29.65, 29.63, 29.56, 29.54, 29.51, 29.47, 29.39, 29.36, 29.31, 29.19, 25.37, 25.17, 25.12, 25.01, 22.68 (56×*C*H~2~), 14.09 (4×ω^Myr^-*C*H~3~, 2×ω^Lau^-*C*H~3~); ^31^P NMR (243 MHz, CDCl~3~) δ −1.61, −1.69; HRMS (ESI) *m*/*z* calcd for C~135~H~211~NO~25~P~2~+Na^+^ 2331.4638 \[M+Na^+^\], found 2331.4618.

### 4-*O*-\[(*R*)-3-(Dodecanoyloxy)tetradecanoyl\]-2-*O*-methyl-6-*O*-phosphoryl-α-[d]{.smallcaps}-mannopyranosyl-(1↔1)-2-deoxy-2-\[(*R*)-3-(dodecanoyloxy)tetradecanoylamino\]-4-*O*-phosphoryl-3-*O*-\[(*R*)-3-(tetradecanoyloxy)tetradecanoyl\]-α-[d]{.smallcaps}-glucopyranoside (**1**) {#sec3.1.8}

A solution of **61** (10 mg, 4.3 μmol) in toluene--MeOH (1 mL, 1:1) was hydrogenated over Pd-black (5 mg, 47 μmol) for 20 h. The mixture was diluted with CH~2~Cl~2~--EtOH (1:1, 10 mL), and the solids were removed by filtration (syringe filter, regenerated cellulose, 45 μm). The filtrate was concentrated, and the residue was purified by size exclusion chromatography on Bio-Beads SX1 (200--400 mesh, 2 × 60 cm, toluene--CH~2~Cl~2~, 3:1). Appropriate fractions were concentrated, and the residue was dissolved in DMSO (2 mL) and freeze-dried to afford **1** (6.0 mg, 3.4 μmol, 79%) as a white solid: *R*~*f*~ = 0.29 (CHCl~3~--MeOH--H~2~O, 50:28:6); ^1^H NMR (600 MHz, CDCl~3~--MeOD, 3:1) δ 5.29 (d, 1H, ^3^*J*~1,2~ = 3.8 Hz, H-1), 5.27--5.22 (m, 4H, H-1′, H-3, 2×β^Myr^-C*H*), 5.14--5.09 (m, 1H, β^Myr^-C*H*), 5.00 (t, 1H, ^3^*J*~4′,5′~ = ^3^*J*~4′,3′~ = 9.7 Hz, H-4′), 4.31 (dt, 1H, ^3^*J* = 9.7 Hz, ^3^*J* = 9.9 Hz, H-4), 4.17 (dd, 1H, ^3^*J*~2,1~ = 3.7 Hz, ^3^*J*~2,3~ = 10.9 Hz, H-2), 4.03 (dd, 1H, ^3^*J*~3′,2′~ = 3.6 Hz, ^3^*J*~3′,4′~ = 9.5 Hz, H-3′), 4.02--3.98 (m, 1H, H-6a′), 3.94--3.87 (m, 2H, H-6a, H-6b′), 3.79--3.75 (m, 2H, H-5′, H-6b), 3.73--3.69 (m, 1H, H-5), 3.49 (dd, 1H, ^3^*J*~2′,1′~ = 1.8 Hz, ^3^*J*~2′,3′~ = 3.5 Hz, H-2′), 3.48 (s, 3H, C*H*~3~, Me), 2.68--2.60 (m, 4H, 2×α^Myr^-C*H*~2~), 2.52--2.45 (m, 2H, α^Myr^-C*H*~2~), 2.33--2.29 (m, 6H, α^Myr^-C*H*~2~, 2×α^Lau^-C*H*~2~), 1.67--1.54 (m, 12H, β^Myr^-C*H*~2~, 2×β^Lau^-C*H2*, 3×γ^Myr^-C*H*~2~), 1.35--1.23 (m, 106H, 53×C*H*~2~), 0.89 (t, 18H, *J* = 7.0 Hz, 4×ω^Myr^-C*H*~3~, 2×ω^Lau^-C*H*~3~); ^31^P NMR (243 MHz, CDCl~3~--MeOD, 3:1) δ 0.38, 0.01; MS (MALDI) *m*/*z* calcd for C~93~H~175~NO~25~P--H 1767.186 \[M-H\]^−^, found 1767.058. For MALDI-TOF MS, 1 μL of a solution of **1** (0.5 mg/mL in CH~2~Cl~2~--EtOH, 1:1) was mixed with 6-aza-2-thiothymine matrix (3 mg/mL EtOH--20 mM aq. ammonium citrate buffer, 1:1).

### 4-*O*-\[(*R*)-3-(Decanoyloxy)tetradecanoyl\]-2-*O*-methyl-6-*O*-phosphoryl-α-mannopyranosyl-(1↔1)-2-deoxy-2-\[(*R*)-3-(dodecanoyloxy)tetradecanoylamino\]-4-*O*-phosphoryl-3-*O*-\[(*R*)-3-(tetradecanoyloxy)tetradecanoyl\]-α-[d]{.smallcaps}-glucopyranoside (**2**) {#sec3.1.9}

Compound **2** (12 mg, 5.3 μmol) was prepared from **62** in a manner similar to the synthesis of **1**, which afforded **2** (8.0 mg, 4.6 μmol, 87%) as a white fluffy solid: *R*~*f*~ = 0.38 (CHCl~3~--MeOH--H~2~O, 50:28:6); ^1^H NMR (600 MHz, CDCl~3~--MeOD, 3:1) δ 5.29 (d, 1H, ^3^*J*~1,2~ = 3.6 Hz, H-1), 5.27--5.21 (m, 4H, H-1′, H-3, 2×β^Myr^-C*H*), 5.14--5.09 (m, 1H, β^Myr^-C*H*), 5.00 (t, 1H, ^3^*J*~4′,5′~ = ^3^*J*~3′,4′~ = 9.7 Hz, H-4′), 4.31 (dt, 1H, ^3^*J*~4,5~ = ^3^*J*~4,3~ = ^3^*J*~4,P~ = 9.7 Hz, H-4), 4.19--4.13 (m, 1H, H-2), 4.03 (dd, 1H, ^3^*J*~3′,2′~ = 3.5 Hz, ^3^*J*~3′,4′~ = 9.5 Hz, H-3′), 4.01--3.98 (m, 1H, H-6a′), 3.94--3.88 (m, 2H, H-6a, H-6b′), 3.79--3.74 (m, 2H, H-5′, H-6b), 3.73--3.69 (m, 1H, H-5), 3.49 (dd, 1H, ^3^*J*~2′,1′~ = 1.8 Hz, ^3^*J*~2′,3′~ = 3.4 Hz, H-2′), 3.48 (s, 3H, C*H*~3~, Me), 2.70--2.60 (m, 4H, 2×α ^Myr^-C*H*~2~), 2.52--2.45 (m, 2H, α^Myr^-C*H*~2~), 2.33--2.29 (m, 6H, α^Myr^-C*H*~2~, α^Lau^-C*H*~2~, α^Cap^-C*H*~2~), 1.65--1.55 (m, 12H, 3×γ ^Myr^-C*H*~2~, β^Myr^-C*H*~2~, β^Lau^-C*H*~2~, β^Cap^-C*H*~2~), 1.37--1.22 (m, 102H, 51×C*H*~2~), 0.89 (t, 18H, *J* = 7.0 Hz, 4×ω ^Myr^-C*H*~3~, ω^Lau^-C*H*~3~, ω^Cap^-C*H*~3~); ^31^P NMR (243 MHz, CDCl~3~--MeOD, 3:1) δ 0.42, 0.01; MS (MALDI) *m*/*z* calcd for C~91~H~171~NO~25~P ~2~ −H 1739.154 \[M-H\]^−^, found 1739.160.

### 4-*O*-\[(*R*)-3-(Dodecanoyloxy)tetradecanoyl\]-2-*O*-methyl*-*α-[d]{.smallcaps}-mannopyranosyl-(1↔1)-2-deoxy-2-\[(*R*)-3-(dodecanoyloxy)tetradecanoylamino\]-4-*O*-phosphoryl-3-*O*-\[(*R*)-3-(tetradecanoyloxy)tetradecanoyl\]-α-[d]{.smallcaps}-glucopyranoside (**3**) {#sec3.1.10}

Compound **3** (5.6 mg, 2.7 μmol) was prepared from **57** in a manner similar to the synthesis of **1**, which afforded **3** (3.7 mg, 2.2 μmol, 81%) as a white fluffy solid: *R*~*f*~ = 0.47 (CHCl~3~--MeOH--H~2~O, 50:28:6); ^1^H NMR (600 MHz, CDCl~3~--MeOD, 3:1) δ 7.16 (d, 1H, ^3^*J*~NH,2~ = 8.3 Hz, N*H*), 5.26--5.17 (m, 5H, H-1, H-1′, H-3, 2×β^Myr^-C*H*), 5.12--5.08 (m, 1H, β^Myr^-C*H*), 5.04 (t, 1H, ^3^*J*~4′,3′~ = ^3^*J*~4′,5′~ = 9.8 Hz, H-4′), 4.30 (dt, 1H, ^3^*J*~4,5~ = ^3^*J*~4,3~ = ^3^*J*~4,P~ = 9.9 Hz, H-4), 4.24--4.19 (m, 1H, H-2), 4.04 (dd, 1H, ^3^*J*~3′,2′~ = 3.5 Hz, ^3^*J*~3′,4′~ = 9.6 Hz, H-3′), 3.94 (dd, 1H, *J* = 2.9 Hz, *J* = 13.0 Hz, H-6a), 3.75--3.71 (m, 1H, H-6b), 3.71--3.67 (m, 1H, H-5), 3.66--3.62 (m, 1H, H-5′), 3.57--3.54 (m, 2H, H-6a′, H-6b′), 3.51--3.48 (m, 1H, H-2′), 3.49 (s, 3H, C*H*~3~, Me), 2.69--2.58 (m, 4H, 2×α^Myr^-C*H*~2~), 2.49 (dd, 1H, *J* = 6.9 Hz, *J* = 14.9 Hz, α^Myr^-C*H*~2~), 2.43 (dd, 1H, *J* = 5.9 Hz, *J* = 14.9 Hz, α^Myr^-C*H*~2~), 2.32--2.28 (m, 6H, α^Myr^-C*H*~2~, 2×α^Lau^-C*H*~2~), 1.67--1.54 (m, 12H, β^Myr^-C*H*~2~, 2×β^Lau^-C*H*~2~, 3×γ^Myr^-C*H*~2~), 1.38--1.22 (m, 106H, 53×C*H*~2~), 0.89 (t, 18, *J* = 7.0 Hz, 4×ω^Myr^-C*H*~3~, 2×ω^Lau^-C*H*~3~); ^31^P NMR (243 MHz, CDCl~3~--MeOD, 3:1) δ 0.68; MS (ESI) *m*/*z* calcd for C~93~H~174~NO~22~P--H 1687.219 \[M-H\]^−^, found 1687.205.

Biological Assays {#sec3.2}
-----------------

### Reagents {#sec3.2.1}

HEK293 stably expressing human TLR4, MD-2, CD14, and a secreted NF-κB-dependent reporter (HEKBlue hTLR4), *E. coli* O111:B4 LPS, *E. coli* serotype R515 *Re*-LPS, *S. minnesota* R595 MPLA (SM-MPLA), and synthetic *E. coli* MPLA were purchased from InvivoGen. Synthetic *E. coli* lipid A was purchased from Peptide Institute. The THP-1 human monocyte-like cell line was obtained from Dr. Rene Devos (Roche Research Ghent) and originally purchased from ATCC. The phorbol ester 12-*O*-tetradecanoylphorbol-13-acetate (TPA) was purchased from Sigma. Lipid A mimetics **1**--**3** were reconstituted in DMSO to provide 1 mg/mL stock solutions. Further dilutions were made with cell medium (RPMI or DMEM) supplemented with 10% FCS so that the final amount of DMSO in the cell culture did not exceed 0.01%.

### hTLR4/MD-2/CD14-Transfected HEK293 Cells (Hek-Blue) Activation Assay {#sec3.2.2}

Growth conditions and activation assay were set as recommended by InvivoGen. The cells were stimulated with the solutions of compounds **1**--**3** or LPS/Re-LPS in DMEM supplemented by 10% FCS at the indicated concentrations. The final amount of DMSO in the cell culture did not exceed 0.005% for **1** and **2** or 0.01% for **3**. The compounds were added in a total volume of 20 μL to 25000 HEK-Blue hTLR4 cells in 180 μL plates and were incubated for 20--24 h at 37 °C and 5% CO~2~. SEAP levels were determined by incubation of 20 μL of challenged cell supernatants with 180 μL of detection reagent (QUANTI-Blue), and the color development was measured at 650 nm using a spectrophotometer (SpectraMAX 190). Data were combined from *n* = 3 independent experiments; error bars indicate standard error of the mean.

### Differentiation and Stimulation of THP-1 Cells {#sec3.2.3}

THP-1 cells were grown in RPMI-1640 cell-culture medium (Life Technologies) that was supplemented with 2 mM [l]{.smallcaps}-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% FCS. Cells were seeded in a 96-well plate at 10^5^ cells/well in 150 μL of complete medium and stimulated by 200 nM TPA for 24 h to induce the differentiation into macrophage-like cells.^[@ref59]^ On the next day the cells were washed twice with complete culture medium to discard the cells that did not adhere, refreshed with 200 μL of complete medium, and left for 1 h to recover. Cells were stimulated with α,α-GM-LAMs **1**--**3** at the indicated concentration and with *E. coliRe*-LPS (or *E. coli* O111:B4 LPS), which were added as solutions in 10 μL of complete medium. The total volume of the well after stimulation reached 220 μL. The cells were incubated for 18 h, and the supernatants were analyzed for TNF-α, IL-8, and MCP-1 by ELISA (BD Biosciences).

### Activation of Mouse Bone Marrow-Derived Macrophages by α,α-GM-LAMs **1**--**3** {#sec3.2.4}

Bone-marrow-derived microphages (BMDMs) were isolated and differentiated from the bone marrow of C57BL/6J mice. The bone marrow was flushed from femur and fibia with RPMI media. The erythrocytes were lysed with 0.88% ammonium chloride, 15 min at 37 °C. A single-cell suspension of the bone marrow cells was then seeded in cell culture flasks at a concentration of 1 × 10^6^ cells/mL in RPMI supplemented with 20% FBS and 40 ng/mL recombinant M-CSF. The cell culture medium was changed on day 3. On day 6, the differentiated cells were trypsinized, counted, and seeded in 24-well plates at a concentration of 1 × 10^6^ cells/mL in RPMI supplemented with 10% FBS. After 24 h, the cells were stimulated with Lipid A mimetics **1**--**3** and with synthetic *E. coli* Lipid A/MPLA (*E. coli* O111:B4 LPS was used as positive control) for 16 h. The nanomolar concentrations of **1**--**3** were calculated according to the MW of the synthetic compounds. The supernatants were then tested for cytokines using Ready-Set-Go ELISA kits (eBioscience).

### Induction of Cytokine Production by α,α-GM-LAMs **1** and **3** in hDCs {#sec3.2.5}

Human peripheral blood monocytes were cultured for 6 days in GM-CSF and IL-4 to receive immature monocyte-derived DCs and were then stimulated with the indicated concentrations of **1** and **3** using 10 ng/mL LPS as positive control (solutions in PRMI containing 10% FCS and 0.005--0.01% DMSO). The amounts of IL-6, IL-12, IL-10, and TNF-α in the supernatants of the cells were analyzed after 24 h by Luminex. Results are representative of three independent experiments for **1** and of two experiments for **3**. Mean values of duplicate examinations ± SD are presented.

Supplementary tables and figures, experimental procedures, and ^1^H NMR, ^13^C NMR, and MALDI-TOF spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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TLR4

:   Toll-like Receptor 4

MD-2

:   myeloid differentiation factor 2

α,α-GM-LAM

:   αGlcN(1↔1)αMan-based Lipid A mimetic

MPLA

:   synthetic *E. coli* monophosphoryl Lipid A

SM-MPLA

:   *S. minnesota* monophosphoryl Lipid A

MyD88

:   myeloid differentiation primary response gene 88
